id	sid	tid	token	lemma	pos
ajrhss-2943	1	1	american	american	PROPN
ajrhss-2943	1	2	journal	journal	PROPN
ajrhss-2943	1	3	of	of	ADP
ajrhss-2943	1	4	research	research	NOUN
ajrhss-2943	1	5	in	in	ADP
ajrhss-2943	1	6	humanities	humanity	NOUN
ajrhss-2943	1	7	and	and	CCONJ
ajrhss-2943	1	8	social	social	ADJ
ajrhss-2943	1	9	sciences	science	NOUN
ajrhss-2943	1	10	issn	issn	PROPN
ajrhss-2943	1	11	(	(	PUNCT
ajrhss-2943	1	12	e	e	NOUN
ajrhss-2943	1	13	):	):	PUNCT
ajrhss-2943	1	14	2832	2832	NUM
ajrhss-2943	1	15	-	-	SYM
ajrhss-2943	1	16	8019	8019	NUM
ajrhss-2943	1	17	volume	volume	NOUN
ajrhss-2943	1	18	36	36	NUM
ajrhss-2943	1	19	,	,	PUNCT
ajrhss-2943	1	20	|	|	ADV
ajrhss-2943	1	21	may	may	AUX
ajrhss-2943	1	22	2025	2025	NUM
ajrhss-2943	1	23	p	p	NOUN
ajrhss-2943	1	24	a	a	DET
ajrhss-2943	1	25	g	g	NOUN
ajrhss-2943	1	26	e	e	NOUN
ajrhss-2943	1	27	|	|	ADV
ajrhss-2943	1	28	71	71	NUM
ajrhss-2943	1	29	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-2943	1	30	assessment	assessment	NOUN
ajrhss-2943	1	31	of	of	ADP
ajrhss-2943	1	32	immunological	immunological	ADJ
ajrhss-2943	1	33	test	test	NOUN
ajrhss-2943	1	34	results	result	NOUN
ajrhss-2943	1	35	in	in	ADP
ajrhss-2943	1	36	diagnosing	diagnose	VERB
ajrhss-2943	1	37	patients	patient	NOUN
ajrhss-2943	1	38	with	with	ADP
ajrhss-2943	1	39	allergic	allergic	ADJ
ajrhss-2943	1	40	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	1	41	akhmedova	akhmedova	VERB
ajrhss-2943	1	42	ziyodakhon	ziyodakhon	PROPN
ajrhss-2943	1	43	anvar	anvar	PROPN
ajrhss-2943	1	44	qizi	qizi	PROPN
ajrhss-2943	1	45	tashkent	tashkent	PROPN
ajrhss-2943	1	46	medical	medical	PROPN
ajrhss-2943	1	47	academy	academy	PROPN
ajrhss-2943	1	48	a	a	DET
ajrhss-2943	1	49	b	b	PROPN
ajrhss-2943	1	50	s	s	ADP
ajrhss-2943	1	51	t	t	PROPN
ajrhss-2943	1	52	r	r	NOUN
ajrhss-2943	1	53	a	a	DET
ajrhss-2943	1	54	c	c	NOUN
ajrhss-2943	1	55	t	t	NOUN
ajrhss-2943	2	1	k	k	X
ajrhss-2943	2	2	e	e	PROPN
ajrhss-2943	2	3	y	y	PROPN
ajrhss-2943	2	4	w	w	NOUN
ajrhss-2943	2	5	o	o	NOUN
ajrhss-2943	2	6	r	r	NOUN
ajrhss-2943	2	7	d	d	X
ajrhss-2943	2	8	s	s	X
ajrhss-2943	2	9	allergic	allergic	ADJ
ajrhss-2943	2	10	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	2	11	is	be	AUX
ajrhss-2943	2	12	an	an	DET
ajrhss-2943	2	13	inflammatory	inflammatory	ADJ
ajrhss-2943	2	14	condition	condition	NOUN
ajrhss-2943	2	15	of	of	ADP
ajrhss-2943	2	16	the	the	DET
ajrhss-2943	2	17	nasal	nasal	ADJ
ajrhss-2943	2	18	mucosa	mucosa	PROPN
ajrhss-2943	2	19	triggered	trigger	VERB
ajrhss-2943	2	20	by	by	ADP
ajrhss-2943	2	21	exposure	exposure	NOUN
ajrhss-2943	2	22	to	to	ADP
ajrhss-2943	2	23	allergens	allergen	NOUN
ajrhss-2943	2	24	,	,	PUNCT
ajrhss-2943	2	25	mediated	mediate	VERB
ajrhss-2943	2	26	primarily	primarily	ADV
ajrhss-2943	2	27	by	by	ADP
ajrhss-2943	2	28	immunoglobulin	immunoglobulin	NOUN
ajrhss-2943	2	29	e	e	PROPN
ajrhss-2943	2	30	(	(	PUNCT
ajrhss-2943	2	31	ige	ige	PROPN
ajrhss-2943	2	32	)	)	PUNCT
ajrhss-2943	2	33	.	.	PUNCT
ajrhss-2943	3	1	understanding	understand	VERB
ajrhss-2943	3	2	the	the	DET
ajrhss-2943	3	3	underlying	underlying	ADJ
ajrhss-2943	3	4	pathogenic	pathogenic	ADJ
ajrhss-2943	3	5	mechanisms	mechanism	NOUN
ajrhss-2943	3	6	is	be	AUX
ajrhss-2943	3	7	essential	essential	ADJ
ajrhss-2943	3	8	for	for	ADP
ajrhss-2943	3	9	prescribing	prescribe	VERB
ajrhss-2943	3	10	effective	effective	ADJ
ajrhss-2943	3	11	and	and	CCONJ
ajrhss-2943	3	12	targeted	target	VERB
ajrhss-2943	3	13	therapy	therapy	NOUN
ajrhss-2943	3	14	[	[	X
ajrhss-2943	3	15	18	18	NUM
ajrhss-2943	3	16	]	]	PUNCT
ajrhss-2943	3	17	.	.	PUNCT
ajrhss-2943	4	1	the	the	DET
ajrhss-2943	4	2	pathogenesis	pathogenesis	NOUN
ajrhss-2943	4	3	of	of	ADP
ajrhss-2943	4	4	allergic	allergic	ADJ
ajrhss-2943	4	5	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	4	6	is	be	AUX
ajrhss-2943	4	7	based	base	VERB
ajrhss-2943	4	8	on	on	ADP
ajrhss-2943	4	9	the	the	DET
ajrhss-2943	4	10	development	development	NOUN
ajrhss-2943	4	11	of	of	ADP
ajrhss-2943	4	12	an	an	DET
ajrhss-2943	4	13	ige	ige	NOUN
ajrhss-2943	4	14	-	-	PUNCT
ajrhss-2943	4	15	mediated	mediate	VERB
ajrhss-2943	4	16	hypersensitivity	hypersensitivity	NOUN
ajrhss-2943	4	17	immune	immune	ADJ
ajrhss-2943	4	18	response	response	NOUN
ajrhss-2943	4	19	initiated	initiate	VERB
ajrhss-2943	4	20	by	by	ADP
ajrhss-2943	4	21	allergens	allergen	NOUN
ajrhss-2943	4	22	penetrating	penetrate	VERB
ajrhss-2943	4	23	the	the	DET
ajrhss-2943	4	24	nasal	nasal	ADJ
ajrhss-2943	4	25	mucosa	mucosa	PROPN
ajrhss-2943	4	26	.	.	PUNCT
ajrhss-2943	5	1	this	this	DET
ajrhss-2943	5	2	process	process	NOUN
ajrhss-2943	5	3	occurs	occur	VERB
ajrhss-2943	5	4	in	in	ADP
ajrhss-2943	5	5	two	two	NUM
ajrhss-2943	5	6	phases	phase	NOUN
ajrhss-2943	5	7	:	:	PUNCT
ajrhss-2943	5	8	early	early	ADJ
ajrhss-2943	5	9	and	and	CCONJ
ajrhss-2943	5	10	late	late	ADV
ajrhss-2943	5	11	,	,	PUNCT
ajrhss-2943	5	12	which	which	PRON
ajrhss-2943	5	13	define	define	VERB
ajrhss-2943	5	14	the	the	DET
ajrhss-2943	5	15	nature	nature	NOUN
ajrhss-2943	5	16	and	and	CCONJ
ajrhss-2943	5	17	progression	progression	NOUN
ajrhss-2943	5	18	of	of	ADP
ajrhss-2943	5	19	clinical	clinical	ADJ
ajrhss-2943	5	20	symptoms	symptom	NOUN
ajrhss-2943	5	21	.	.	PUNCT
ajrhss-2943	6	1	both	both	DET
ajrhss-2943	6	2	phases	phase	NOUN
ajrhss-2943	6	3	involve	involve	VERB
ajrhss-2943	6	4	the	the	DET
ajrhss-2943	6	5	activation	activation	NOUN
ajrhss-2943	6	6	of	of	ADP
ajrhss-2943	6	7	mast	mast	NOUN
ajrhss-2943	6	8	cells	cell	NOUN
ajrhss-2943	6	9	,	,	PUNCT
ajrhss-2943	6	10	eosinophils	eosinophil	NOUN
ajrhss-2943	6	11	,	,	PUNCT
ajrhss-2943	6	12	lymphocytes	lymphocyte	NOUN
ajrhss-2943	6	13	,	,	PUNCT
ajrhss-2943	6	14	and	and	CCONJ
ajrhss-2943	6	15	basophils	basophils	PROPN
ajrhss-2943	6	16	.	.	PUNCT
ajrhss-2943	7	1	the	the	DET
ajrhss-2943	7	2	initial	initial	ADJ
ajrhss-2943	7	3	phase	phase	NOUN
ajrhss-2943	7	4	of	of	ADP
ajrhss-2943	7	5	allergic	allergic	ADJ
ajrhss-2943	7	6	hyperreactivity	hyperreactivity	NOUN
ajrhss-2943	7	7	is	be	AUX
ajrhss-2943	7	8	characterized	characterize	VERB
ajrhss-2943	7	9	by	by	ADP
ajrhss-2943	7	10	plasma	plasma	NOUN
ajrhss-2943	7	11	exudation	exudation	NOUN
ajrhss-2943	7	12	containing	contain	VERB
ajrhss-2943	7	13	high	high	ADJ
ajrhss-2943	7	14	levels	level	NOUN
ajrhss-2943	7	15	of	of	ADP
ajrhss-2943	7	16	biologically	biologically	ADV
ajrhss-2943	7	17	active	active	ADJ
ajrhss-2943	7	18	substances	substance	NOUN
ajrhss-2943	7	19	such	such	ADJ
ajrhss-2943	7	20	as	as	ADP
ajrhss-2943	7	21	histamine	histamine	NOUN
ajrhss-2943	7	22	,	,	PUNCT
ajrhss-2943	7	23	kinins	kinin	NOUN
ajrhss-2943	7	24	,	,	PUNCT
ajrhss-2943	7	25	and	and	CCONJ
ajrhss-2943	7	26	immunoglobulins	immunoglobulin	NOUN
ajrhss-2943	7	27	.	.	PUNCT
ajrhss-2943	8	1	consequently	consequently	ADV
ajrhss-2943	8	2	,	,	PUNCT
ajrhss-2943	8	3	nasal	nasal	PROPN
ajrhss-2943	8	4	congestion	congestion	NOUN
ajrhss-2943	8	5	and	and	CCONJ
ajrhss-2943	8	6	rhinorrhea	rhinorrhea	PROPN
ajrhss-2943	8	7	are	be	AUX
ajrhss-2943	8	8	prominent	prominent	ADJ
ajrhss-2943	8	9	symptoms	symptom	NOUN
ajrhss-2943	8	10	in	in	ADP
ajrhss-2943	8	11	the	the	DET
ajrhss-2943	8	12	early	early	ADJ
ajrhss-2943	8	13	phase	phase	NOUN
ajrhss-2943	8	14	.	.	PUNCT
ajrhss-2943	9	1	during	during	ADP
ajrhss-2943	9	2	the	the	DET
ajrhss-2943	9	3	exudation	exudation	NOUN
ajrhss-2943	9	4	process	process	NOUN
ajrhss-2943	9	5	,	,	PUNCT
ajrhss-2943	9	6	histamine	histamine	NOUN
ajrhss-2943	9	7	released	release	VERB
ajrhss-2943	9	8	onto	onto	ADP
ajrhss-2943	9	9	the	the	DET
ajrhss-2943	9	10	nasal	nasal	ADJ
ajrhss-2943	9	11	mucosa	mucosa	PROPN
ajrhss-2943	9	12	irritates	irritate	VERB
ajrhss-2943	9	13	nerve	nerve	NOUN
ajrhss-2943	9	14	endings	ending	NOUN
ajrhss-2943	9	15	through	through	ADP
ajrhss-2943	9	16	interepithelial	interepithelial	ADJ
ajrhss-2943	9	17	junctions	junction	NOUN
ajrhss-2943	9	18	,	,	PUNCT
ajrhss-2943	9	19	causing	cause	VERB
ajrhss-2943	9	20	itching	itching	NOUN
ajrhss-2943	9	21	and	and	CCONJ
ajrhss-2943	9	22	sneezing	sneeze	VERB
ajrhss-2943	9	23	in	in	ADP
ajrhss-2943	9	24	the	the	DET
ajrhss-2943	9	25	nose	nose	NOUN
ajrhss-2943	10	1	[	[	X
ajrhss-2943	10	2	12,17	12,17	NUM
ajrhss-2943	10	3	]	]	PUNCT
ajrhss-2943	10	4	.	.	PUNCT
ajrhss-2943	11	1	introduction	introduction	NOUN
ajrhss-2943	11	2	atopic	atopic	NOUN
ajrhss-2943	11	3	diseases	disease	NOUN
ajrhss-2943	11	4	such	such	ADJ
ajrhss-2943	11	5	as	as	ADP
ajrhss-2943	11	6	allergic	allergic	ADJ
ajrhss-2943	11	7	rhinitis	rhinitis	NOUN
ajrhss-2943	11	8	,	,	PUNCT
ajrhss-2943	11	9	bronchial	bronchial	ADJ
ajrhss-2943	11	10	asthma	asthma	NOUN
ajrhss-2943	11	11	,	,	PUNCT
ajrhss-2943	11	12	and	and	CCONJ
ajrhss-2943	11	13	drug	drug	NOUN
ajrhss-2943	11	14	allergies	allergy	NOUN
ajrhss-2943	11	15	are	be	AUX
ajrhss-2943	11	16	characterized	characterize	VERB
ajrhss-2943	11	17	by	by	ADP
ajrhss-2943	11	18	igemediated	igemediate	VERB
ajrhss-2943	11	19	immune	immune	ADJ
ajrhss-2943	11	20	responses	response	NOUN
ajrhss-2943	11	21	against	against	ADP
ajrhss-2943	11	22	specific	specific	ADJ
ajrhss-2943	11	23	antigens	antigen	NOUN
ajrhss-2943	11	24	(	(	PUNCT
ajrhss-2943	11	25	allergens	allergen	NOUN
ajrhss-2943	11	26	)	)	PUNCT
ajrhss-2943	11	27	.	.	PUNCT
ajrhss-2943	12	1	both	both	PRON
ajrhss-2943	12	2	environmental	environmental	ADJ
ajrhss-2943	12	3	factors	factor	NOUN
ajrhss-2943	12	4	and	and	CCONJ
ajrhss-2943	12	5	genetic	genetic	ADJ
ajrhss-2943	12	6	predisposition	predisposition	NOUN
ajrhss-2943	12	7	contribute	contribute	VERB
ajrhss-2943	12	8	to	to	ADP
ajrhss-2943	12	9	disease	disease	NOUN
ajrhss-2943	12	10	development	development	NOUN
ajrhss-2943	12	11	.	.	PUNCT
ajrhss-2943	13	1	ige	ige	PROPN
ajrhss-2943	13	2	-	-	PUNCT
ajrhss-2943	13	3	mediated	mediate	VERB
ajrhss-2943	13	4	allergic	allergic	ADJ
ajrhss-2943	13	5	reactions	reaction	NOUN
ajrhss-2943	13	6	often	often	ADV
ajrhss-2943	13	7	affect	affect	VERB
ajrhss-2943	13	8	mucous	mucous	ADJ
ajrhss-2943	13	9	membranes	membrane	NOUN
ajrhss-2943	13	10	(	(	PUNCT
ajrhss-2943	13	11	nasal	nasal	ADJ
ajrhss-2943	13	12	,	,	PUNCT
ajrhss-2943	13	13	conjunctival	conjunctival	NOUN
ajrhss-2943	13	14	,	,	PUNCT
ajrhss-2943	13	15	respiratory	respiratory	ADJ
ajrhss-2943	13	16	tract	tract	NOUN
ajrhss-2943	13	17	,	,	PUNCT
ajrhss-2943	13	18	gastrointestinal	gastrointestinal	ADJ
ajrhss-2943	13	19	tract	tract	NOUN
ajrhss-2943	13	20	)	)	PUNCT
ajrhss-2943	13	21	or	or	CCONJ
ajrhss-2943	13	22	the	the	DET
ajrhss-2943	13	23	skin	skin	NOUN
ajrhss-2943	13	24	,	,	PUNCT
ajrhss-2943	13	25	where	where	SCONJ
ajrhss-2943	13	26	mast	mast	NOUN
ajrhss-2943	13	27	cells	cell	NOUN
ajrhss-2943	13	28	coated	coat	VERB
ajrhss-2943	13	29	with	with	ADP
ajrhss-2943	13	30	ige	ige	PROPN
ajrhss-2943	13	31	molecules	molecule	NOUN
ajrhss-2943	13	32	are	be	AUX
ajrhss-2943	13	33	abundant	abundant	ADJ
ajrhss-2943	13	34	[	[	X
ajrhss-2943	13	35	3	3	NUM
ajrhss-2943	13	36	]	]	PUNCT
ajrhss-2943	13	37	.	.	PUNCT
ajrhss-2943	14	1	the	the	DET
ajrhss-2943	14	2	primary	primary	ADJ
ajrhss-2943	14	3	diagnostic	diagnostic	ADJ
ajrhss-2943	14	4	methods	method	NOUN
ajrhss-2943	14	5	for	for	ADP
ajrhss-2943	14	6	allergies	allergy	NOUN
ajrhss-2943	14	7	include	include	VERB
ajrhss-2943	14	8	skin	skin	NOUN
ajrhss-2943	14	9	prick	prick	NOUN
ajrhss-2943	14	10	tests	test	NOUN
ajrhss-2943	14	11	conducted	conduct	VERB
ajrhss-2943	14	12	by	by	ADP
ajrhss-2943	14	13	trained	train	VERB
ajrhss-2943	14	14	specialists	specialist	NOUN
ajrhss-2943	14	15	in	in	ADP
ajrhss-2943	14	16	allergology	allergology	NOUN
ajrhss-2943	14	17	clinics	clinic	NOUN
ajrhss-2943	14	18	.	.	PUNCT
ajrhss-2943	15	1	additionally	additionally	ADV
ajrhss-2943	15	2	,	,	PUNCT
ajrhss-2943	15	3	levels	level	NOUN
ajrhss-2943	15	4	of	of	ADP
ajrhss-2943	15	5	total	total	ADJ
ajrhss-2943	15	6	and	and	CCONJ
ajrhss-2943	15	7	allergen	allergen	NOUN
ajrhss-2943	15	8	-	-	PUNCT
ajrhss-2943	15	9	specific	specific	ADJ
ajrhss-2943	15	10	ige	ige	NOUN
ajrhss-2943	15	11	in	in	ADP
ajrhss-2943	15	12	blood	blood	NOUN
ajrhss-2943	15	13	serum	serum	NOUN
ajrhss-2943	15	14	can	can	AUX
ajrhss-2943	15	15	be	be	AUX
ajrhss-2943	15	16	measured	measure	VERB
ajrhss-2943	15	17	through	through	ADP
ajrhss-2943	15	18	various	various	ADJ
ajrhss-2943	15	19	immunological	immunological	ADJ
ajrhss-2943	15	20	laboratory	laboratory	NOUN
ajrhss-2943	15	21	techniques	technique	NOUN
ajrhss-2943	15	22	.	.	PUNCT
ajrhss-2943	16	1	the	the	DET
ajrhss-2943	16	2	treatment	treatment	NOUN
ajrhss-2943	16	3	of	of	ADP
ajrhss-2943	16	4	allergic	allergic	ADJ
ajrhss-2943	16	5	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	16	6	remains	remain	VERB
ajrhss-2943	16	7	a	a	DET
ajrhss-2943	16	8	pressing	press	VERB
ajrhss-2943	16	9	issue	issue	NOUN
ajrhss-2943	16	10	due	due	ADP
ajrhss-2943	16	11	to	to	ADP
ajrhss-2943	16	12	the	the	DET
ajrhss-2943	16	13	increasing	increase	VERB
ajrhss-2943	16	14	prevalence	prevalence	NOUN
ajrhss-2943	16	15	,	,	PUNCT
ajrhss-2943	16	16	exacerbation	exacerbation	NOUN
ajrhss-2943	16	17	of	of	ADP
ajrhss-2943	16	18	allergic	allergic	ADJ
ajrhss-2943	16	19	processes	process	NOUN
ajrhss-2943	16	20	,	,	PUNCT
ajrhss-2943	16	21	occurrence	occurrence	NOUN
ajrhss-2943	16	22	of	of	ADP
ajrhss-2943	16	23	infectious	infectious	ADJ
ajrhss-2943	16	24	complications	complication	NOUN
ajrhss-2943	16	25	,	,	PUNCT
ajrhss-2943	16	26	and	and	CCONJ
ajrhss-2943	16	27	the	the	DET
ajrhss-2943	16	28	development	development	NOUN
ajrhss-2943	16	29	of	of	ADP
ajrhss-2943	16	30	polysensitization	polysensitization	NOUN
ajrhss-2943	16	31	[	[	X
ajrhss-2943	16	32	11,12,13,14	11,12,13,14	ADV
ajrhss-2943	16	33	]	]	PUNCT
ajrhss-2943	16	34	.	.	PUNCT
ajrhss-2943	17	1	upon	upon	SCONJ
ajrhss-2943	17	2	initiation	initiation	NOUN
ajrhss-2943	17	3	of	of	ADP
ajrhss-2943	17	4	an	an	DET
ajrhss-2943	17	5	allergic	allergic	ADJ
ajrhss-2943	17	6	reaction	reaction	NOUN
ajrhss-2943	17	7	,	,	PUNCT
ajrhss-2943	17	8	plasma	plasma	NOUN
ajrhss-2943	17	9	cells	cell	NOUN
ajrhss-2943	17	10	produce	produce	VERB
ajrhss-2943	17	11	allergenspecific	allergenspecific	PROPN
ajrhss-2943	17	12	ige	ige	PROPN
ajrhss-2943	17	13	antibodies	antibodie	VERB
ajrhss-2943	17	14	.	.	PUNCT
ajrhss-2943	18	1	once	once	ADV
ajrhss-2943	18	2	formed	form	VERB
ajrhss-2943	18	3	and	and	CCONJ
ajrhss-2943	18	4	released	release	VERB
ajrhss-2943	18	5	into	into	ADP
ajrhss-2943	18	6	the	the	DET
ajrhss-2943	18	7	bloodstream	bloodstream	NOUN
ajrhss-2943	18	8	,	,	PUNCT
ajrhss-2943	18	9	ige	ige	PROPN
ajrhss-2943	18	10	molecules	molecule	NOUN
ajrhss-2943	18	11	bind	bind	VERB
ajrhss-2943	18	12	to	to	ADP
ajrhss-2943	18	13	receptors	receptor	NOUN
ajrhss-2943	18	14	on	on	ADP
ajrhss-2943	18	15	mast	mast	NOUN
ajrhss-2943	18	16	cells	cell	NOUN
ajrhss-2943	18	17	located	locate	VERB
ajrhss-2943	18	18	in	in	ADP
ajrhss-2943	18	19	the	the	DET
ajrhss-2943	18	20	skin	skin	NOUN
ajrhss-2943	18	21	,	,	PUNCT
ajrhss-2943	18	22	nasal	nasal	NOUN
ajrhss-2943	18	23	,	,	PUNCT
ajrhss-2943	18	24	and	and	CCONJ
ajrhss-2943	18	25	respiratory	respiratory	ADJ
ajrhss-2943	18	26	mucosa	mucosa	NOUN
ajrhss-2943	18	27	,	,	PUNCT
ajrhss-2943	18	28	providing	provide	VERB
ajrhss-2943	18	29	allergen	allergen	NOUN
ajrhss-2943	18	30	-	-	PUNCT
ajrhss-2943	18	31	specific	specific	ADJ
ajrhss-2943	18	32	receptors	receptor	NOUN
ajrhss-2943	18	33	for	for	ADP
ajrhss-2943	18	34	subsequent	subsequent	ADJ
ajrhss-2943	18	35	allergen	allergen	NOUN
ajrhss-2943	18	36	exposure	exposure	NOUN
ajrhss-2943	18	37	[	[	X
ajrhss-2943	18	38	6	6	NUM
ajrhss-2943	18	39	]	]	PUNCT
ajrhss-2943	18	40	.	.	PUNCT
ajrhss-2943	19	1	american	american	PROPN
ajrhss-2943	19	2	journal	journal	PROPN
ajrhss-2943	19	3	of	of	ADP
ajrhss-2943	19	4	research	research	NOUN
ajrhss-2943	19	5	in	in	ADP
ajrhss-2943	19	6	humanities	humanity	NOUN
ajrhss-2943	19	7	and	and	CCONJ
ajrhss-2943	19	8	social	social	ADJ
ajrhss-2943	19	9	sciences	science	NOUN
ajrhss-2943	19	10	volume	volume	NOUN
ajrhss-2943	19	11	36	36	NUM
ajrhss-2943	19	12	may	may	PROPN
ajrhss-2943	19	13	2025	2025	NUM
ajrhss-2943	19	14	p	p	NOUN
ajrhss-2943	19	15	a	a	DET
ajrhss-2943	19	16	g	g	NOUN
ajrhss-2943	19	17	e	e	NOUN
ajrhss-2943	19	18	|	|	ADV
ajrhss-2943	19	19	72	72	NUM
ajrhss-2943	19	20	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-2943	19	21	regulatory	regulatory	ADJ
ajrhss-2943	19	22	mechanisms	mechanism	NOUN
ajrhss-2943	19	23	controlling	control	VERB
ajrhss-2943	19	24	ige	ige	PROPN
ajrhss-2943	19	25	synthesis	synthesis	NOUN
ajrhss-2943	19	26	differ	differ	VERB
ajrhss-2943	19	27	from	from	ADP
ajrhss-2943	19	28	those	those	PRON
ajrhss-2943	19	29	of	of	ADP
ajrhss-2943	19	30	other	other	ADJ
ajrhss-2943	19	31	immunoglobulin	immunoglobulin	NOUN
ajrhss-2943	19	32	classes	class	NOUN
ajrhss-2943	19	33	.	.	PUNCT
ajrhss-2943	20	1	ige	ige	PROPN
ajrhss-2943	20	2	levels	level	NOUN
ajrhss-2943	20	3	gradually	gradually	ADV
ajrhss-2943	20	4	increase	increase	VERB
ajrhss-2943	20	5	during	during	ADP
ajrhss-2943	20	6	infancy	infancy	NOUN
ajrhss-2943	20	7	and	and	CCONJ
ajrhss-2943	20	8	typically	typically	ADV
ajrhss-2943	20	9	reach	reach	VERB
ajrhss-2943	20	10	adult	adult	NOUN
ajrhss-2943	20	11	values	value	NOUN
ajrhss-2943	20	12	by	by	ADP
ajrhss-2943	20	13	the	the	DET
ajrhss-2943	20	14	age	age	NOUN
ajrhss-2943	20	15	of	of	ADP
ajrhss-2943	20	16	15–20	15–20	NUM
ajrhss-2943	20	17	years	year	NOUN
ajrhss-2943	20	18	.	.	PUNCT
ajrhss-2943	21	1	these	these	DET
ajrhss-2943	21	2	ige	ige	PROPN
ajrhss-2943	21	3	levels	level	NOUN
ajrhss-2943	21	4	are	be	AUX
ajrhss-2943	21	5	usually	usually	ADV
ajrhss-2943	21	6	low	low	ADJ
ajrhss-2943	21	7	,	,	PUNCT
ajrhss-2943	21	8	and	and	CCONJ
ajrhss-2943	21	9	allergen	allergen	NOUN
ajrhss-2943	21	10	-	-	PUNCT
ajrhss-2943	21	11	specific	specific	ADJ
ajrhss-2943	21	12	ige	ige	NOUN
ajrhss-2943	21	13	responses	response	NOUN
ajrhss-2943	21	14	are	be	AUX
ajrhss-2943	21	15	commonly	commonly	ADV
ajrhss-2943	21	16	associated	associate	VERB
ajrhss-2943	21	17	with	with	ADP
ajrhss-2943	21	18	a	a	DET
ajrhss-2943	21	19	marked	mark	VERB
ajrhss-2943	21	20	increase	increase	NOUN
ajrhss-2943	21	21	in	in	ADP
ajrhss-2943	21	22	total	total	ADJ
ajrhss-2943	21	23	serum	serum	PROPN
ajrhss-2943	21	24	ige	ige	PROPN
ajrhss-2943	21	25	concentration	concentration	NOUN
ajrhss-2943	21	26	.	.	PUNCT
ajrhss-2943	22	1	it	it	PRON
ajrhss-2943	22	2	should	should	AUX
ajrhss-2943	22	3	be	be	AUX
ajrhss-2943	22	4	noted	note	VERB
ajrhss-2943	22	5	that	that	SCONJ
ajrhss-2943	22	6	even	even	ADV
ajrhss-2943	22	7	though	though	SCONJ
ajrhss-2943	22	8	total	total	ADJ
ajrhss-2943	22	9	ige	ige	PROPN
ajrhss-2943	22	10	levels	level	NOUN
ajrhss-2943	22	11	in	in	ADP
ajrhss-2943	22	12	healthy	healthy	ADJ
ajrhss-2943	22	13	individuals	individual	NOUN
ajrhss-2943	22	14	are	be	AUX
ajrhss-2943	22	15	generally	generally	ADV
ajrhss-2943	22	16	low	low	ADJ
ajrhss-2943	22	17	,	,	PUNCT
ajrhss-2943	22	18	higher	high	ADJ
ajrhss-2943	22	19	concentrations	concentration	NOUN
ajrhss-2943	22	20	of	of	ADP
ajrhss-2943	22	21	antigen	antigen	NOUN
ajrhss-2943	22	22	-	-	PUNCT
ajrhss-2943	22	23	specific	specific	ADJ
ajrhss-2943	22	24	antibodies	antibody	NOUN
ajrhss-2943	22	25	may	may	AUX
ajrhss-2943	22	26	exist	exist	VERB
ajrhss-2943	22	27	and	and	CCONJ
ajrhss-2943	22	28	potentially	potentially	ADV
ajrhss-2943	22	29	lead	lead	VERB
ajrhss-2943	22	30	to	to	ADP
ajrhss-2943	22	31	heightened	heighten	VERB
ajrhss-2943	22	32	sensitivity	sensitivity	NOUN
ajrhss-2943	22	33	after	after	ADP
ajrhss-2943	22	34	exposure	exposure	NOUN
ajrhss-2943	22	35	to	to	ADP
ajrhss-2943	22	36	corresponding	correspond	VERB
ajrhss-2943	22	37	foreign	foreign	ADJ
ajrhss-2943	22	38	molecules	molecule	NOUN
ajrhss-2943	22	39	[	[	X
ajrhss-2943	22	40	7	7	NUM
ajrhss-2943	22	41	]	]	PUNCT
ajrhss-2943	22	42	.	.	PUNCT
ajrhss-2943	23	1	objective	objective	NOUN
ajrhss-2943	23	2	:	:	PUNCT
ajrhss-2943	23	3	to	to	PART
ajrhss-2943	23	4	evaluate	evaluate	VERB
ajrhss-2943	23	5	the	the	DET
ajrhss-2943	23	6	role	role	NOUN
ajrhss-2943	23	7	of	of	ADP
ajrhss-2943	23	8	cytokines	cytokine	NOUN
ajrhss-2943	23	9	il-4	il-4	ADV
ajrhss-2943	23	10	,	,	PUNCT
ajrhss-2943	23	11	il-13	il-13	PRON
ajrhss-2943	23	12	,	,	PUNCT
ajrhss-2943	23	13	and	and	CCONJ
ajrhss-2943	23	14	ige	ige	PROPN
ajrhss-2943	23	15	molecules	molecule	NOUN
ajrhss-2943	23	16	in	in	ADP
ajrhss-2943	23	17	the	the	DET
ajrhss-2943	23	18	pathogenesis	pathogenesis	NOUN
ajrhss-2943	23	19	of	of	ADP
ajrhss-2943	23	20	allergic	allergic	ADJ
ajrhss-2943	23	21	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	23	22	by	by	ADP
ajrhss-2943	23	23	comparing	compare	VERB
ajrhss-2943	23	24	test	test	NOUN
ajrhss-2943	23	25	results	result	NOUN
ajrhss-2943	23	26	between	between	ADP
ajrhss-2943	23	27	patients	patient	NOUN
ajrhss-2943	23	28	and	and	CCONJ
ajrhss-2943	23	29	healthy	healthy	ADJ
ajrhss-2943	23	30	individuals	individual	NOUN
ajrhss-2943	23	31	.	.	PUNCT
ajrhss-2943	24	1	materials	material	NOUN
ajrhss-2943	24	2	and	and	CCONJ
ajrhss-2943	24	3	methods	method	NOUN
ajrhss-2943	24	4	the	the	DET
ajrhss-2943	24	5	study	study	NOUN
ajrhss-2943	24	6	was	be	AUX
ajrhss-2943	24	7	conducted	conduct	VERB
ajrhss-2943	24	8	at	at	ADP
ajrhss-2943	24	9	the	the	DET
ajrhss-2943	24	10	clinical	clinical	ADJ
ajrhss-2943	24	11	base	base	NOUN
ajrhss-2943	24	12	of	of	ADP
ajrhss-2943	24	13	tashkent	tashkent	PROPN
ajrhss-2943	24	14	medical	medical	PROPN
ajrhss-2943	24	15	academy	academy	PROPN
ajrhss-2943	24	16	.	.	PUNCT
ajrhss-2943	25	1	patients	patient	NOUN
ajrhss-2943	25	2	were	be	AUX
ajrhss-2943	25	3	examined	examine	VERB
ajrhss-2943	25	4	and	and	CCONJ
ajrhss-2943	25	5	laboratory	laboratory	NOUN
ajrhss-2943	25	6	tests	test	NOUN
ajrhss-2943	25	7	were	be	AUX
ajrhss-2943	25	8	performed	perform	VERB
ajrhss-2943	25	9	in	in	ADP
ajrhss-2943	25	10	the	the	DET
ajrhss-2943	25	11	immunology	immunology	NOUN
ajrhss-2943	25	12	and	and	CCONJ
ajrhss-2943	25	13	human	human	ADJ
ajrhss-2943	25	14	genomics	genomic	NOUN
ajrhss-2943	25	15	laboratory	laboratory	NOUN
ajrhss-2943	25	16	.	.	PUNCT
ajrhss-2943	26	1	during	during	ADP
ajrhss-2943	26	2	the	the	DET
ajrhss-2943	26	3	period	period	NOUN
ajrhss-2943	26	4	from	from	ADP
ajrhss-2943	26	5	january	january	PROPN
ajrhss-2943	26	6	to	to	ADP
ajrhss-2943	26	7	december	december	PROPN
ajrhss-2943	26	8	2022	2022	NUM
ajrhss-2943	26	9	,	,	PUNCT
ajrhss-2943	26	10	a	a	DET
ajrhss-2943	26	11	total	total	NOUN
ajrhss-2943	26	12	of	of	ADP
ajrhss-2943	26	13	80	80	NUM
ajrhss-2943	26	14	participants	participant	NOUN
ajrhss-2943	26	15	were	be	AUX
ajrhss-2943	26	16	enrolled	enrol	VERB
ajrhss-2943	26	17	,	,	PUNCT
ajrhss-2943	26	18	including	include	VERB
ajrhss-2943	26	19	60	60	NUM
ajrhss-2943	26	20	patients	patient	NOUN
ajrhss-2943	26	21	diagnosed	diagnose	VERB
ajrhss-2943	26	22	with	with	ADP
ajrhss-2943	26	23	allergic	allergic	ADJ
ajrhss-2943	26	24	rhinitis	rhinitis	NOUN
ajrhss-2943	26	25	(	(	PUNCT
ajrhss-2943	26	26	ar	ar	NOUN
ajrhss-2943	26	27	)	)	PUNCT
ajrhss-2943	26	28	and	and	CCONJ
ajrhss-2943	26	29	28	28	NUM
ajrhss-2943	26	30	healthy	healthy	ADJ
ajrhss-2943	26	31	controls	control	NOUN
ajrhss-2943	26	32	.	.	PUNCT
ajrhss-2943	27	1	among	among	ADP
ajrhss-2943	27	2	the	the	DET
ajrhss-2943	27	3	patients	patient	NOUN
ajrhss-2943	27	4	,	,	PUNCT
ajrhss-2943	27	5	24	24	NUM
ajrhss-2943	27	6	(	(	PUNCT
ajrhss-2943	27	7	48.65	48.65	NUM
ajrhss-2943	27	8	%	%	NOUN
ajrhss-2943	27	9	)	)	PUNCT
ajrhss-2943	27	10	had	have	AUX
ajrhss-2943	27	11	intermittent	intermittent	ADJ
ajrhss-2943	27	12	allergic	allergic	ADJ
ajrhss-2943	27	13	rhinitis	rhinitis	NOUN
ajrhss-2943	27	14	(	(	PUNCT
ajrhss-2943	27	15	iar	iar	PROPN
ajrhss-2943	27	16	)	)	PUNCT
ajrhss-2943	27	17	and	and	CCONJ
ajrhss-2943	27	18	26	26	NUM
ajrhss-2943	27	19	(	(	PUNCT
ajrhss-2943	27	20	51.35	51.35	NUM
ajrhss-2943	27	21	%	%	NOUN
ajrhss-2943	27	22	)	)	PUNCT
ajrhss-2943	27	23	had	have	VERB
ajrhss-2943	27	24	persistent	persistent	ADJ
ajrhss-2943	27	25	allergic	allergic	ADJ
ajrhss-2943	27	26	rhinitis	rhinitis	NOUN
ajrhss-2943	27	27	(	(	PUNCT
ajrhss-2943	27	28	par	par	NOUN
ajrhss-2943	27	29	)	)	PUNCT
ajrhss-2943	27	30	.	.	PUNCT
ajrhss-2943	28	1	the	the	DET
ajrhss-2943	28	2	mean	mean	ADJ
ajrhss-2943	28	3	age	age	NOUN
ajrhss-2943	28	4	of	of	ADP
ajrhss-2943	28	5	patients	patient	NOUN
ajrhss-2943	28	6	with	with	ADP
ajrhss-2943	28	7	ar	ar	PROPN
ajrhss-2943	28	8	was	be	AUX
ajrhss-2943	28	9	45.59	45.59	NUM
ajrhss-2943	28	10	±	±	NUM
ajrhss-2943	28	11	16.37	16.37	NUM
ajrhss-2943	28	12	years	year	NOUN
ajrhss-2943	28	13	(	(	PUNCT
ajrhss-2943	28	14	range	range	NOUN
ajrhss-2943	28	15	22–84	22–84	NUM
ajrhss-2943	28	16	)	)	PUNCT
ajrhss-2943	28	17	,	,	PUNCT
ajrhss-2943	28	18	while	while	SCONJ
ajrhss-2943	28	19	the	the	DET
ajrhss-2943	28	20	control	control	NOUN
ajrhss-2943	28	21	group	group	NOUN
ajrhss-2943	28	22	had	have	VERB
ajrhss-2943	28	23	a	a	DET
ajrhss-2943	28	24	mean	mean	ADJ
ajrhss-2943	28	25	age	age	NOUN
ajrhss-2943	28	26	of	of	ADP
ajrhss-2943	28	27	42.96	42.96	NUM
ajrhss-2943	28	28	±	±	NUM
ajrhss-2943	28	29	15.06	15.06	NUM
ajrhss-2943	28	30	years	year	NOUN
ajrhss-2943	28	31	(	(	PUNCT
ajrhss-2943	28	32	range	range	NOUN
ajrhss-2943	28	33	19–63	19–63	NUM
ajrhss-2943	28	34	)	)	PUNCT
ajrhss-2943	28	35	.	.	PUNCT
ajrhss-2943	29	1	the	the	DET
ajrhss-2943	29	2	patient	patient	ADJ
ajrhss-2943	29	3	group	group	NOUN
ajrhss-2943	29	4	consisted	consist	VERB
ajrhss-2943	29	5	of	of	ADP
ajrhss-2943	29	6	32	32	NUM
ajrhss-2943	29	7	(	(	PUNCT
ajrhss-2943	29	8	53.7	53.7	NUM
ajrhss-2943	29	9	%	%	NOUN
ajrhss-2943	29	10	)	)	PUNCT
ajrhss-2943	29	11	females	female	NOUN
ajrhss-2943	29	12	and	and	CCONJ
ajrhss-2943	29	13	28	28	NUM
ajrhss-2943	29	14	(	(	PUNCT
ajrhss-2943	29	15	46.3	46.3	NUM
ajrhss-2943	29	16	%	%	NOUN
ajrhss-2943	29	17	)	)	PUNCT
ajrhss-2943	29	18	males	male	NOUN
ajrhss-2943	29	19	;	;	PUNCT
ajrhss-2943	29	20	the	the	DET
ajrhss-2943	29	21	control	control	NOUN
ajrhss-2943	29	22	group	group	NOUN
ajrhss-2943	29	23	comprised	comprise	VERB
ajrhss-2943	29	24	14	14	NUM
ajrhss-2943	29	25	(	(	PUNCT
ajrhss-2943	29	26	62.1	62.1	NUM
ajrhss-2943	29	27	%	%	NOUN
ajrhss-2943	29	28	)	)	PUNCT
ajrhss-2943	29	29	females	female	NOUN
ajrhss-2943	29	30	and	and	CCONJ
ajrhss-2943	29	31	6	6	NUM
ajrhss-2943	29	32	(	(	PUNCT
ajrhss-2943	29	33	37.9	37.9	NUM
ajrhss-2943	29	34	%	%	NOUN
ajrhss-2943	29	35	)	)	PUNCT
ajrhss-2943	29	36	males	male	NOUN
ajrhss-2943	29	37	.	.	PUNCT
ajrhss-2943	30	1	patients	patient	NOUN
ajrhss-2943	30	2	with	with	ADP
ajrhss-2943	30	3	both	both	DET
ajrhss-2943	30	4	forms	form	NOUN
ajrhss-2943	30	5	of	of	ADP
ajrhss-2943	30	6	ar	ar	NOUN
ajrhss-2943	30	7	had	have	AUX
ajrhss-2943	30	8	not	not	PART
ajrhss-2943	30	9	used	use	VERB
ajrhss-2943	30	10	any	any	DET
ajrhss-2943	30	11	antiallergic	antiallergic	ADJ
ajrhss-2943	30	12	drugs	drug	NOUN
ajrhss-2943	30	13	,	,	PUNCT
ajrhss-2943	30	14	antihistamines	antihistamine	NOUN
ajrhss-2943	30	15	,	,	PUNCT
ajrhss-2943	30	16	topical	topical	ADJ
ajrhss-2943	30	17	or	or	CCONJ
ajrhss-2943	30	18	systemic	systemic	ADJ
ajrhss-2943	30	19	corticosteroids	corticosteroid	NOUN
ajrhss-2943	30	20	,	,	PUNCT
ajrhss-2943	30	21	or	or	CCONJ
ajrhss-2943	30	22	non	non	ADJ
ajrhss-2943	30	23	-	-	ADJ
ajrhss-2943	30	24	steroidal	steroidal	ADJ
ajrhss-2943	30	25	anti	anti	ADJ
ajrhss-2943	30	26	-	-	ADJ
ajrhss-2943	30	27	inflammatory	inflammatory	ADJ
ajrhss-2943	30	28	drugs	drug	NOUN
ajrhss-2943	30	29	(	(	PUNCT
ajrhss-2943	30	30	nsaids	nsaid	NOUN
ajrhss-2943	30	31	)	)	PUNCT
ajrhss-2943	30	32	for	for	ADP
ajrhss-2943	30	33	at	at	ADV
ajrhss-2943	30	34	least	least	ADV
ajrhss-2943	30	35	one	one	NUM
ajrhss-2943	30	36	month	month	NOUN
ajrhss-2943	30	37	prior	prior	ADV
ajrhss-2943	30	38	to	to	ADP
ajrhss-2943	30	39	the	the	DET
ajrhss-2943	30	40	study	study	NOUN
ajrhss-2943	30	41	.	.	PUNCT
ajrhss-2943	31	1	results	result	VERB
ajrhss-2943	31	2	statistical	statistical	ADJ
ajrhss-2943	31	3	analysis	analysis	NOUN
ajrhss-2943	31	4	showed	show	VERB
ajrhss-2943	31	5	that	that	SCONJ
ajrhss-2943	31	6	serum	serum	NOUN
ajrhss-2943	31	7	ige	ige	PROPN
ajrhss-2943	31	8	levels	level	NOUN
ajrhss-2943	31	9	in	in	ADP
ajrhss-2943	31	10	patients	patient	NOUN
ajrhss-2943	31	11	with	with	ADP
ajrhss-2943	31	12	ar	ar	NOUN
ajrhss-2943	31	13	were	be	AUX
ajrhss-2943	31	14	higher	high	ADJ
ajrhss-2943	31	15	compared	compare	VERB
ajrhss-2943	31	16	to	to	ADP
ajrhss-2943	31	17	controls	control	NOUN
ajrhss-2943	31	18	,	,	PUNCT
ajrhss-2943	31	19	although	although	SCONJ
ajrhss-2943	31	20	the	the	DET
ajrhss-2943	31	21	difference	difference	NOUN
ajrhss-2943	31	22	was	be	AUX
ajrhss-2943	31	23	not	not	PART
ajrhss-2943	31	24	statistically	statistically	ADV
ajrhss-2943	31	25	significant	significant	ADJ
ajrhss-2943	31	26	(	(	PUNCT
ajrhss-2943	31	27	237.84	237.84	NUM
ajrhss-2943	31	28	±	±	NUM
ajrhss-2943	31	29	38.71	38.71	NUM
ajrhss-2943	31	30	u	u	NOUN
ajrhss-2943	31	31	/	/	SYM
ajrhss-2943	31	32	ml	ml	X
ajrhss-2943	31	33	vs.	vs.	ADP
ajrhss-2943	31	34	175.44	175.44	NUM
ajrhss-2943	31	35	±	±	NUM
ajrhss-2943	31	36	79.89	79.89	NUM
ajrhss-2943	31	37	u	u	NOUN
ajrhss-2943	31	38	/	/	SYM
ajrhss-2943	31	39	ml	ml	PROPN
ajrhss-2943	31	40	,	,	PUNCT
ajrhss-2943	31	41	p	p	X
ajrhss-2943	31	42	=	=	NOUN
ajrhss-2943	31	43	0.474	0.474	NUM
ajrhss-2943	31	44	)	)	PUNCT
ajrhss-2943	31	45	.	.	PUNCT
ajrhss-2943	32	1	similarly	similarly	ADV
ajrhss-2943	32	2	,	,	PUNCT
ajrhss-2943	32	3	higher	high	ADJ
ajrhss-2943	32	4	il-4	il-4	NOUN
ajrhss-2943	32	5	levels	level	NOUN
ajrhss-2943	32	6	were	be	AUX
ajrhss-2943	32	7	observed	observe	VERB
ajrhss-2943	32	8	in	in	ADP
ajrhss-2943	32	9	the	the	DET
ajrhss-2943	32	10	patient	patient	NOUN
ajrhss-2943	32	11	group	group	NOUN
ajrhss-2943	32	12	compared	compare	VERB
ajrhss-2943	32	13	to	to	ADP
ajrhss-2943	32	14	controls	control	NOUN
ajrhss-2943	32	15	(	(	PUNCT
ajrhss-2943	32	16	29.48	29.48	NUM
ajrhss-2943	32	17	±	±	NUM
ajrhss-2943	32	18	17.77	17.77	NUM
ajrhss-2943	32	19	pg	pg	NOUN
ajrhss-2943	32	20	/	/	SYM
ajrhss-2943	32	21	ml	ml	X
ajrhss-2943	32	22	vs.	vs.	ADP
ajrhss-2943	32	23	7.88	7.88	NUM
ajrhss-2943	32	24	±	±	NUM
ajrhss-2943	32	25	4.70	4.70	NUM
ajrhss-2943	32	26	pg	pg	NOUN
ajrhss-2943	32	27	/	/	SYM
ajrhss-2943	32	28	ml	ml	PROPN
ajrhss-2943	32	29	,	,	PUNCT
ajrhss-2943	32	30	p	p	X
ajrhss-2943	32	31	=	=	NOUN
ajrhss-2943	32	32	0.188	0.188	NUM
ajrhss-2943	32	33	)	)	PUNCT
ajrhss-2943	32	34	,	,	PUNCT
ajrhss-2943	32	35	but	but	CCONJ
ajrhss-2943	32	36	this	this	DET
ajrhss-2943	32	37	difference	difference	NOUN
ajrhss-2943	32	38	was	be	AUX
ajrhss-2943	32	39	not	not	PART
ajrhss-2943	32	40	significant	significant	ADJ
ajrhss-2943	32	41	(	(	PUNCT
ajrhss-2943	32	42	figure	figure	NOUN
ajrhss-2943	32	43	1	1	NUM
ajrhss-2943	32	44	)	)	PUNCT
ajrhss-2943	32	45	.	.	PUNCT
ajrhss-2943	33	1	no	no	DET
ajrhss-2943	33	2	significant	significant	ADJ
ajrhss-2943	33	3	difference	difference	NOUN
ajrhss-2943	33	4	was	be	AUX
ajrhss-2943	33	5	found	find	VERB
ajrhss-2943	33	6	in	in	ADP
ajrhss-2943	33	7	il-4	il-4	NOUN
ajrhss-2943	33	8	levels	level	NOUN
ajrhss-2943	33	9	between	between	ADP
ajrhss-2943	33	10	patients	patient	NOUN
ajrhss-2943	33	11	with	with	ADP
ajrhss-2943	33	12	ar	ar	NOUN
ajrhss-2943	33	13	and	and	CCONJ
ajrhss-2943	33	14	healthy	healthy	ADJ
ajrhss-2943	33	15	controls	control	NOUN
ajrhss-2943	33	16	when	when	SCONJ
ajrhss-2943	33	17	measured	measure	VERB
ajrhss-2943	33	18	in	in	ADP
ajrhss-2943	33	19	plasma	plasma	NOUN
ajrhss-2943	33	20	(	(	PUNCT
ajrhss-2943	33	21	3.02	3.02	NUM
ajrhss-2943	33	22	±	±	NUM
ajrhss-2943	33	23	0.44	0.44	NUM
ajrhss-2943	33	24	pg	pg	NOUN
ajrhss-2943	33	25	/	/	SYM
ajrhss-2943	33	26	ml	ml	X
ajrhss-2943	33	27	vs.	vs.	ADP
ajrhss-2943	33	28	2.31	2.31	NUM
ajrhss-2943	33	29	±	±	NUM
ajrhss-2943	33	30	0.12	0.12	NUM
ajrhss-2943	33	31	pg	pg	NOUN
ajrhss-2943	33	32	/	/	SYM
ajrhss-2943	33	33	ml	ml	PROPN
ajrhss-2943	33	34	,	,	PUNCT
ajrhss-2943	33	35	p	p	X
ajrhss-2943	33	36	=	=	NOUN
ajrhss-2943	33	37	0.668	0.668	NUM
ajrhss-2943	33	38	)	)	PUNCT
ajrhss-2943	33	39	.	.	PUNCT
ajrhss-2943	34	1	seasonal	seasonal	ADJ
ajrhss-2943	34	2	ar	ar	PROPN
ajrhss-2943	34	3	patients	patient	NOUN
ajrhss-2943	34	4	showed	show	VERB
ajrhss-2943	34	5	higher	high	ADJ
ajrhss-2943	34	6	il-4	il-4	NOUN
ajrhss-2943	34	7	levels	level	NOUN
ajrhss-2943	34	8	than	than	ADP
ajrhss-2943	34	9	those	those	PRON
ajrhss-2943	34	10	with	with	ADP
ajrhss-2943	34	11	persistent	persistent	ADJ
ajrhss-2943	34	12	ar	ar	PROPN
ajrhss-2943	34	13	(	(	PUNCT
ajrhss-2943	34	14	3.65	3.65	NUM
ajrhss-2943	34	15	±	±	NUM
ajrhss-2943	34	16	0.67	0.67	NUM
ajrhss-2943	34	17	pg	pg	NOUN
ajrhss-2943	34	18	/	/	SYM
ajrhss-2943	34	19	ml	ml	X
ajrhss-2943	34	20	vs.	vs.	ADP
ajrhss-2943	34	21	2.39	2.39	NUM
ajrhss-2943	34	22	±	±	NUM
ajrhss-2943	34	23	0.2	0.2	NUM
ajrhss-2943	34	24	pg	pg	NOUN
ajrhss-2943	34	25	/	/	SYM
ajrhss-2943	34	26	ml	ml	PROPN
ajrhss-2943	34	27	,	,	PUNCT
ajrhss-2943	34	28	p	p	X
ajrhss-2943	34	29	=	=	NOUN
ajrhss-2943	34	30	0.651	0.651	NUM
ajrhss-2943	34	31	)	)	PUNCT
ajrhss-2943	34	32	.	.	PUNCT
ajrhss-2943	35	1	no	no	DET
ajrhss-2943	35	2	statistically	statistically	ADV
ajrhss-2943	35	3	significant	significant	ADJ
ajrhss-2943	35	4	differences	difference	NOUN
ajrhss-2943	35	5	in	in	ADP
ajrhss-2943	35	6	il-5	il-5	NOUN
ajrhss-2943	35	7	plasma	plasma	NOUN
ajrhss-2943	35	8	levels	level	NOUN
ajrhss-2943	35	9	were	be	AUX
ajrhss-2943	35	10	found	find	VERB
ajrhss-2943	35	11	between	between	ADP
ajrhss-2943	35	12	ar	ar	NOUN
ajrhss-2943	35	13	patients	patient	NOUN
ajrhss-2943	35	14	and	and	CCONJ
ajrhss-2943	35	15	controls	control	NOUN
ajrhss-2943	35	16	(	(	PUNCT
ajrhss-2943	35	17	6.31	6.31	NUM
ajrhss-2943	35	18	±	±	NUM
ajrhss-2943	35	19	1.24	1.24	NUM
ajrhss-2943	35	20	pg	pg	NOUN
ajrhss-2943	35	21	/	/	SYM
ajrhss-2943	35	22	ml	ml	X
ajrhss-2943	35	23	vs.	vs.	ADP
ajrhss-2943	35	24	5.61	5.61	NUM
ajrhss-2943	35	25	±	±	NUM
ajrhss-2943	35	26	2.2	2.2	NUM
ajrhss-2943	35	27	pg	pg	NOUN
ajrhss-2943	35	28	/	/	SYM
ajrhss-2943	35	29	ml	ml	PROPN
ajrhss-2943	35	30	,	,	PUNCT
ajrhss-2943	35	31	p	p	X
ajrhss-2943	35	32	=	=	NOUN
ajrhss-2943	35	33	0.842	0.842	NUM
ajrhss-2943	35	34	)	)	PUNCT
ajrhss-2943	35	35	.	.	PUNCT
ajrhss-2943	36	1	however	however	ADV
ajrhss-2943	36	2	,	,	PUNCT
ajrhss-2943	36	3	patients	patient	NOUN
ajrhss-2943	36	4	with	with	ADP
ajrhss-2943	36	5	intermittent	intermittent	PROPN
ajrhss-2943	36	6	ar	ar	PROPN
ajrhss-2943	36	7	tended	tend	VERB
ajrhss-2943	36	8	to	to	PART
ajrhss-2943	36	9	have	have	VERB
ajrhss-2943	36	10	higher	high	ADJ
ajrhss-2943	36	11	il-5	il-5	NOUN
ajrhss-2943	36	12	levels	level	NOUN
ajrhss-2943	36	13	(	(	PUNCT
ajrhss-2943	36	14	13.43	13.43	NUM
ajrhss-2943	36	15	±	±	NUM
ajrhss-2943	36	16	4.77	4.77	NUM
ajrhss-2943	36	17	pg	pg	NOUN
ajrhss-2943	36	18	/	/	SYM
ajrhss-2943	36	19	ml	ml	VERB
ajrhss-2943	36	20	)	)	PUNCT
ajrhss-2943	36	21	compared	compare	VERB
ajrhss-2943	36	22	to	to	ADP
ajrhss-2943	36	23	others	other	NOUN
ajrhss-2943	36	24	(	(	PUNCT
ajrhss-2943	36	25	3.84	3.84	NUM
ajrhss-2943	36	26	±	±	NUM
ajrhss-2943	36	27	1.81	1.81	NUM
ajrhss-2943	36	28	pg	pg	NOUN
ajrhss-2943	36	29	/	/	SYM
ajrhss-2943	36	30	ml	ml	PROPN
ajrhss-2943	36	31	,	,	PUNCT
ajrhss-2943	36	32	p	p	X
ajrhss-2943	36	33	=	=	NOUN
ajrhss-2943	36	34	0.088	0.088	NUM
ajrhss-2943	36	35	)	)	PUNCT
ajrhss-2943	36	36	.	.	PUNCT
ajrhss-2943	37	1	though	though	SCONJ
ajrhss-2943	37	2	not	not	PART
ajrhss-2943	37	3	statistically	statistically	ADV
ajrhss-2943	37	4	significant	significant	ADJ
ajrhss-2943	37	5	,	,	PUNCT
ajrhss-2943	37	6	il-13	il-13	PUNCT
ajrhss-2943	37	7	levels	level	NOUN
ajrhss-2943	37	8	were	be	AUX
ajrhss-2943	37	9	lower	low	ADJ
ajrhss-2943	37	10	in	in	ADP
ajrhss-2943	37	11	controls	control	NOUN
ajrhss-2943	37	12	(	(	PUNCT
ajrhss-2943	37	13	5.04	5.04	NUM
ajrhss-2943	37	14	±	±	NUM
ajrhss-2943	37	15	3.75	3.75	NUM
ajrhss-2943	37	16	pg	pg	NOUN
ajrhss-2943	37	17	/	/	SYM
ajrhss-2943	37	18	ml	ml	VERB
ajrhss-2943	37	19	)	)	PUNCT
ajrhss-2943	37	20	compared	compare	VERB
ajrhss-2943	37	21	to	to	ADP
ajrhss-2943	37	22	patients	patient	NOUN
ajrhss-2943	37	23	with	with	ADP
ajrhss-2943	37	24	intermittent	intermittent	PROPN
ajrhss-2943	37	25	ar	ar	PROPN
ajrhss-2943	37	26	(	(	PUNCT
ajrhss-2943	37	27	15.05	15.05	NUM
ajrhss-2943	37	28	±	±	NUM
ajrhss-2943	37	29	5.77	5.77	NUM
ajrhss-2943	37	30	pg	pg	NOUN
ajrhss-2943	37	31	/	/	SYM
ajrhss-2943	37	32	ml	ml	PROPN
ajrhss-2943	37	33	,	,	PUNCT
ajrhss-2943	37	34	p	p	X
ajrhss-2943	37	35	=	=	NOUN
ajrhss-2943	37	36	0.296	0.296	NUM
ajrhss-2943	37	37	)	)	PUNCT
ajrhss-2943	37	38	and	and	CCONJ
ajrhss-2943	37	39	persistent	persistent	ADJ
ajrhss-2943	37	40	ar	ar	PROPN
ajrhss-2943	37	41	(	(	PUNCT
ajrhss-2943	37	42	16.76	16.76	NUM
ajrhss-2943	37	43	±	±	NUM
ajrhss-2943	37	44	7.4	7.4	NUM
ajrhss-2943	37	45	pg	pg	NOUN
ajrhss-2943	37	46	/	/	SYM
ajrhss-2943	37	47	ml	ml	PROPN
ajrhss-2943	37	48	,	,	PUNCT
ajrhss-2943	37	49	p	p	X
ajrhss-2943	37	50	=	=	NOUN
ajrhss-2943	37	51	0.433	0.433	NUM
ajrhss-2943	37	52	)	)	PUNCT
ajrhss-2943	37	53	.	.	PUNCT
ajrhss-2943	38	1	overweight	overweight	ADJ
ajrhss-2943	38	2	patients	patient	NOUN
ajrhss-2943	38	3	tended	tend	VERB
ajrhss-2943	38	4	to	to	PART
ajrhss-2943	38	5	have	have	VERB
ajrhss-2943	38	6	higher	high	ADJ
ajrhss-2943	38	7	il-4	il-4	X
ajrhss-2943	38	8	plasma	plasma	NOUN
ajrhss-2943	38	9	levels	level	NOUN
ajrhss-2943	38	10	(	(	PUNCT
ajrhss-2943	38	11	61.80	61.80	NUM
ajrhss-2943	38	12	±	±	NUM
ajrhss-2943	38	13	40.0	40.0	NUM
ajrhss-2943	38	14	pg	pg	NOUN
ajrhss-2943	38	15	/	/	SYM
ajrhss-2943	38	16	ml	ml	NOUN
ajrhss-2943	38	17	)	)	PUNCT
ajrhss-2943	38	18	than	than	ADP
ajrhss-2943	38	19	normal	normal	ADJ
ajrhss-2943	38	20	weight	weight	NOUN
ajrhss-2943	38	21	(	(	PUNCT
ajrhss-2943	38	22	2.81	2.81	NUM
ajrhss-2943	38	23	±	±	NUM
ajrhss-2943	38	24	0.58	0.58	NUM
ajrhss-2943	38	25	pg	pg	NOUN
ajrhss-2943	38	26	/	/	SYM
ajrhss-2943	38	27	ml	ml	PROPN
ajrhss-2943	38	28	,	,	PUNCT
ajrhss-2943	38	29	p	p	X
ajrhss-2943	38	30	=	=	NOUN
ajrhss-2943	38	31	0.160	0.160	NUM
ajrhss-2943	38	32	)	)	PUNCT
ajrhss-2943	38	33	and	and	CCONJ
ajrhss-2943	38	34	underweight	underweight	NOUN
ajrhss-2943	38	35	patients	patient	NOUN
ajrhss-2943	38	36	(	(	PUNCT
ajrhss-2943	38	37	10.30	10.30	NUM
ajrhss-2943	38	38	±	±	NUM
ajrhss-2943	38	39	5.59	5.59	NUM
ajrhss-2943	38	40	pg	pg	NOUN
ajrhss-2943	38	41	/	/	SYM
ajrhss-2943	38	42	ml	ml	PROPN
ajrhss-2943	38	43	,	,	PUNCT
ajrhss-2943	38	44	p	p	NOUN
ajrhss-2943	38	45	=	=	NOUN
ajrhss-2943	38	46	0.220	0.220	NUM
ajrhss-2943	38	47	)	)	PUNCT
ajrhss-2943	38	48	.	.	PUNCT
ajrhss-2943	39	1	il-13	il-13	PUNCT
ajrhss-2943	39	2	concentrations	concentration	NOUN
ajrhss-2943	39	3	were	be	AUX
ajrhss-2943	39	4	significantly	significantly	ADV
ajrhss-2943	39	5	elevated	elevate	VERB
ajrhss-2943	39	6	in	in	ADP
ajrhss-2943	39	7	overweight	overweight	ADJ
ajrhss-2943	39	8	patients	patient	NOUN
ajrhss-2943	39	9	compared	compare	VERB
ajrhss-2943	39	10	to	to	ADP
ajrhss-2943	39	11	those	those	PRON
ajrhss-2943	39	12	with	with	ADP
ajrhss-2943	39	13	normal	normal	ADJ
ajrhss-2943	39	14	weight	weight	NOUN
ajrhss-2943	39	15	(	(	PUNCT
ajrhss-2943	39	16	24.99	24.99	NUM
ajrhss-2943	39	17	±	±	NUM
ajrhss-2943	39	18	8.9	8.9	NUM
ajrhss-2943	39	19	pg	pg	NOUN
ajrhss-2943	39	20	/	/	SYM
ajrhss-2943	39	21	ml	ml	X
ajrhss-2943	39	22	vs.	vs.	ADP
ajrhss-2943	39	23	7.57	7.57	NUM
ajrhss-2943	39	24	±	±	NUM
ajrhss-2943	39	25	3.73	3.73	NUM
ajrhss-2943	39	26	pg	pg	NOUN
ajrhss-2943	39	27	/	/	SYM
ajrhss-2943	39	28	ml	ml	PROPN
ajrhss-2943	39	29	,	,	PUNCT
ajrhss-2943	39	30	p	p	X
ajrhss-2943	39	31	=	=	NOUN
ajrhss-2943	39	32	0.093	0.093	NUM
ajrhss-2943	39	33	)	)	PUNCT
ajrhss-2943	39	34	.	.	PUNCT
ajrhss-2943	40	1	when	when	SCONJ
ajrhss-2943	40	2	comparing	compare	VERB
ajrhss-2943	40	3	patients	patient	NOUN
ajrhss-2943	40	4	with	with	ADP
ajrhss-2943	40	5	ar	ar	NOUN
ajrhss-2943	40	6	based	base	VERB
ajrhss-2943	40	7	on	on	ADP
ajrhss-2943	40	8	the	the	DET
ajrhss-2943	40	9	presence	presence	NOUN
ajrhss-2943	40	10	of	of	ADP
ajrhss-2943	40	11	nasal	nasal	PROPN
ajrhss-2943	40	12	polyposis	polyposis	NOUN
ajrhss-2943	40	13	,	,	PUNCT
ajrhss-2943	40	14	some	some	DET
ajrhss-2943	40	15	differences	difference	NOUN
ajrhss-2943	40	16	in	in	ADP
ajrhss-2943	40	17	cytokine	cytokine	ADJ
ajrhss-2943	40	18	levels	level	NOUN
ajrhss-2943	40	19	were	be	AUX
ajrhss-2943	40	20	noted	note	VERB
ajrhss-2943	40	21	.	.	PUNCT
ajrhss-2943	41	1	patients	patient	NOUN
ajrhss-2943	41	2	with	with	ADP
ajrhss-2943	41	3	nasal	nasal	ADJ
ajrhss-2943	41	4	polyposis	polyposis	NOUN
ajrhss-2943	41	5	showed	show	VERB
ajrhss-2943	41	6	a	a	DET
ajrhss-2943	41	7	trend	trend	NOUN
ajrhss-2943	41	8	toward	toward	ADP
ajrhss-2943	41	9	lower	low	ADJ
ajrhss-2943	41	10	il-4	il-4	NOUN
ajrhss-2943	41	11	(	(	PUNCT
ajrhss-2943	41	12	4.20	4.20	NUM
ajrhss-2943	41	13	±	±	NUM
ajrhss-2943	41	14	american	american	PROPN
ajrhss-2943	41	15	journal	journal	PROPN
ajrhss-2943	41	16	of	of	ADP
ajrhss-2943	41	17	research	research	NOUN
ajrhss-2943	41	18	in	in	ADP
ajrhss-2943	41	19	humanities	humanity	NOUN
ajrhss-2943	41	20	and	and	CCONJ
ajrhss-2943	41	21	social	social	ADJ
ajrhss-2943	41	22	sciences	science	NOUN
ajrhss-2943	41	23	volume	volume	NOUN
ajrhss-2943	41	24	36	36	NUM
ajrhss-2943	41	25	may	may	PROPN
ajrhss-2943	41	26	2025	2025	NUM
ajrhss-2943	41	27	p	p	NOUN
ajrhss-2943	41	28	a	a	DET
ajrhss-2943	41	29	g	g	NOUN
ajrhss-2943	41	30	e	e	NOUN
ajrhss-2943	42	1	|	|	ADV
ajrhss-2943	42	2	73	73	NUM
ajrhss-2943	42	3	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-2943	42	4	1.6	1.6	NUM
ajrhss-2943	42	5	pg	pg	NOUN
ajrhss-2943	42	6	/	/	SYM
ajrhss-2943	42	7	ml	ml	NOUN
ajrhss-2943	42	8	)	)	PUNCT
ajrhss-2943	42	9	and	and	CCONJ
ajrhss-2943	42	10	il-5	il-5	PRON
ajrhss-2943	42	11	(	(	PUNCT
ajrhss-2943	42	12	5.77	5.77	NUM
ajrhss-2943	42	13	±	±	NUM
ajrhss-2943	42	14	1.3	1.3	NUM
ajrhss-2943	42	15	pg	pg	NOUN
ajrhss-2943	42	16	/	/	SYM
ajrhss-2943	42	17	ml	ml	NOUN
ajrhss-2943	42	18	)	)	PUNCT
ajrhss-2943	42	19	levels	level	NOUN
ajrhss-2943	42	20	compared	compare	VERB
ajrhss-2943	42	21	to	to	ADP
ajrhss-2943	42	22	those	those	PRON
ajrhss-2943	42	23	without	without	ADP
ajrhss-2943	42	24	polyposis	polyposis	NOUN
ajrhss-2943	42	25	(	(	PUNCT
ajrhss-2943	42	26	il-4	il-4	NOUN
ajrhss-2943	42	27	:	:	PUNCT
ajrhss-2943	42	28	35.00	35.00	NUM
ajrhss-2943	42	29	±	±	NUM
ajrhss-2943	42	30	21.59	21.59	NUM
ajrhss-2943	42	31	pg	pg	NOUN
ajrhss-2943	42	32	/	/	SYM
ajrhss-2943	42	33	ml	ml	PROPN
ajrhss-2943	42	34	,	,	PUNCT
ajrhss-2943	42	35	p	p	X
ajrhss-2943	42	36	=	=	NOUN
ajrhss-2943	42	37	0.165	0.165	NUM
ajrhss-2943	42	38	;	;	PUNCT
ajrhss-2943	42	39	il-5	il-5	NUM
ajrhss-2943	42	40	:	:	PUNCT
ajrhss-2943	42	41	8.8	8.8	NUM
ajrhss-2943	42	42	±	±	NUM
ajrhss-2943	42	43	3.66	3.66	NUM
ajrhss-2943	42	44	pg	pg	NOUN
ajrhss-2943	42	45	/	/	SYM
ajrhss-2943	42	46	ml	ml	PROPN
ajrhss-2943	42	47	,	,	PUNCT
ajrhss-2943	42	48	p	p	X
ajrhss-2943	42	49	=	=	NOUN
ajrhss-2943	42	50	0.459	0.459	NUM
ajrhss-2943	42	51	)	)	PUNCT
ajrhss-2943	42	52	(	(	PUNCT
ajrhss-2943	42	53	figure	figure	NOUN
ajrhss-2943	42	54	5	5	NUM
ajrhss-2943	42	55	)	)	PUNCT
ajrhss-2943	42	56	.	.	PUNCT
ajrhss-2943	43	1	conversely	conversely	ADV
ajrhss-2943	43	2	,	,	PUNCT
ajrhss-2943	43	3	il-13	il-13	PUNCT
ajrhss-2943	43	4	levels	level	NOUN
ajrhss-2943	43	5	were	be	AUX
ajrhss-2943	43	6	higher	high	ADJ
ajrhss-2943	43	7	in	in	ADP
ajrhss-2943	43	8	patients	patient	NOUN
ajrhss-2943	43	9	with	with	ADP
ajrhss-2943	43	10	nasal	nasal	ADJ
ajrhss-2943	43	11	polyposis	polyposis	NOUN
ajrhss-2943	43	12	compared	compare	VERB
ajrhss-2943	43	13	to	to	ADP
ajrhss-2943	43	14	those	those	PRON
ajrhss-2943	43	15	without	without	ADP
ajrhss-2943	43	16	(	(	PUNCT
ajrhss-2943	43	17	31.43	31.43	NUM
ajrhss-2943	43	18	±	±	NUM
ajrhss-2943	43	19	17.68	17.68	NUM
ajrhss-2943	43	20	pg	pg	NOUN
ajrhss-2943	43	21	/	/	SYM
ajrhss-2943	43	22	ml	ml	X
ajrhss-2943	43	23	vs.	vs.	ADP
ajrhss-2943	43	24	13.69	13.69	NUM
ajrhss-2943	43	25	±	±	NUM
ajrhss-2943	43	26	4.55	4.55	NUM
ajrhss-2943	43	27	pg	pg	NOUN
ajrhss-2943	43	28	/	/	SYM
ajrhss-2943	43	29	ml	ml	PROPN
ajrhss-2943	43	30	,	,	PUNCT
ajrhss-2943	43	31	p	p	X
ajrhss-2943	43	32	=	=	NOUN
ajrhss-2943	43	33	0.493	0.493	NUM
ajrhss-2943	43	34	)	)	PUNCT
ajrhss-2943	43	35	.	.	PUNCT
ajrhss-2943	44	1	discussion	discussion	NOUN
ajrhss-2943	44	2	interaction	interaction	NOUN
ajrhss-2943	44	3	between	between	ADP
ajrhss-2943	44	4	environmental	environmental	ADJ
ajrhss-2943	44	5	allergens	allergen	NOUN
ajrhss-2943	44	6	and	and	CCONJ
ajrhss-2943	44	7	specific	specific	ADJ
ajrhss-2943	44	8	ige	ige	PROPN
ajrhss-2943	44	9	antibodies	antibody	NOUN
ajrhss-2943	44	10	is	be	AUX
ajrhss-2943	44	11	a	a	DET
ajrhss-2943	44	12	key	key	ADJ
ajrhss-2943	44	13	factor	factor	NOUN
ajrhss-2943	44	14	in	in	ADP
ajrhss-2943	44	15	allergic	allergic	ADJ
ajrhss-2943	44	16	airway	airway	NOUN
ajrhss-2943	44	17	reactions	reaction	NOUN
ajrhss-2943	44	18	and	and	CCONJ
ajrhss-2943	44	19	represents	represent	VERB
ajrhss-2943	44	20	a	a	DET
ajrhss-2943	44	21	major	major	ADJ
ajrhss-2943	44	22	pathogenic	pathogenic	ADJ
ajrhss-2943	44	23	mechanism	mechanism	NOUN
ajrhss-2943	44	24	triggering	trigger	VERB
ajrhss-2943	44	25	allergic	allergic	ADJ
ajrhss-2943	44	26	rhinitis	rhinitis	NOUN
ajrhss-2943	44	27	and	and	CCONJ
ajrhss-2943	44	28	bronchial	bronchial	ADJ
ajrhss-2943	44	29	asthma	asthma	NOUN
ajrhss-2943	44	30	symptoms	symptom	NOUN
ajrhss-2943	44	31	.	.	PUNCT
ajrhss-2943	45	1	the	the	DET
ajrhss-2943	45	2	initial	initial	ADJ
ajrhss-2943	45	3	immunopathogenic	immunopathogenic	ADJ
ajrhss-2943	45	4	response	response	NOUN
ajrhss-2943	45	5	required	require	VERB
ajrhss-2943	45	6	for	for	ADP
ajrhss-2943	45	7	disease	disease	NOUN
ajrhss-2943	45	8	onset	onset	NOUN
ajrhss-2943	45	9	is	be	AUX
ajrhss-2943	45	10	increased	increase	VERB
ajrhss-2943	45	11	production	production	NOUN
ajrhss-2943	45	12	of	of	ADP
ajrhss-2943	45	13	ige	ige	PROPN
ajrhss-2943	45	14	antibodies	antibodie	VERB
ajrhss-2943	45	15	specific	specific	ADJ
ajrhss-2943	45	16	to	to	ADP
ajrhss-2943	45	17	environmental	environmental	ADJ
ajrhss-2943	45	18	allergens	allergen	NOUN
ajrhss-2943	45	19	such	such	ADJ
ajrhss-2943	45	20	as	as	ADP
ajrhss-2943	45	21	house	house	NOUN
ajrhss-2943	45	22	dust	dust	NOUN
ajrhss-2943	45	23	and	and	CCONJ
ajrhss-2943	45	24	pollen	pollen	NOUN
ajrhss-2943	45	25	.	.	PUNCT
ajrhss-2943	46	1	several	several	ADJ
ajrhss-2943	46	2	studies	study	NOUN
ajrhss-2943	46	3	have	have	AUX
ajrhss-2943	46	4	shown	show	VERB
ajrhss-2943	46	5	that	that	SCONJ
ajrhss-2943	46	6	ige	ige	PROPN
ajrhss-2943	46	7	production	production	NOUN
ajrhss-2943	46	8	is	be	AUX
ajrhss-2943	46	9	regulated	regulate	VERB
ajrhss-2943	46	10	by	by	ADP
ajrhss-2943	46	11	antigen	antigen	NOUN
ajrhss-2943	46	12	-	-	PUNCT
ajrhss-2943	46	13	specific	specific	ADJ
ajrhss-2943	46	14	helper	helper	NOUN
ajrhss-2943	46	15	and	and	CCONJ
ajrhss-2943	46	16	suppressor	suppressor	NOUN
ajrhss-2943	46	17	t	t	PROPN
ajrhss-2943	46	18	cells	cell	NOUN
ajrhss-2943	46	19	and	and	CCONJ
ajrhss-2943	46	20	is	be	AUX
ajrhss-2943	46	21	influenced	influence	VERB
ajrhss-2943	46	22	by	by	ADP
ajrhss-2943	46	23	isotype	isotype	NOUN
ajrhss-2943	46	24	-	-	PUNCT
ajrhss-2943	46	25	specific	specific	ADJ
ajrhss-2943	46	26	factors	factor	NOUN
ajrhss-2943	46	27	.	.	PUNCT
ajrhss-2943	47	1	regulation	regulation	NOUN
ajrhss-2943	47	2	of	of	ADP
ajrhss-2943	47	3	ige	ige	NOUN
ajrhss-2943	47	4	synthesis	synthesis	NOUN
ajrhss-2943	47	5	involves	involve	VERB
ajrhss-2943	47	6	th2	th2	PROPN
ajrhss-2943	47	7	cells	cell	NOUN
ajrhss-2943	47	8	and	and	CCONJ
ajrhss-2943	47	9	cytokines	cytokine	NOUN
ajrhss-2943	47	10	produced	produce	VERB
ajrhss-2943	47	11	by	by	ADP
ajrhss-2943	47	12	b	b	PROPN
ajrhss-2943	47	13	lymphocytes	lymphocyte	NOUN
ajrhss-2943	47	14	,	,	PUNCT
ajrhss-2943	47	15	which	which	PRON
ajrhss-2943	47	16	play	play	VERB
ajrhss-2943	47	17	a	a	DET
ajrhss-2943	47	18	critical	critical	ADJ
ajrhss-2943	47	19	role	role	NOUN
ajrhss-2943	47	20	in	in	ADP
ajrhss-2943	47	21	initiating	initiate	VERB
ajrhss-2943	47	22	and	and	CCONJ
ajrhss-2943	47	23	enhancing	enhance	VERB
ajrhss-2943	47	24	specific	specific	ADJ
ajrhss-2943	47	25	ige	ige	NOUN
ajrhss-2943	47	26	antibody	antibody	NOUN
ajrhss-2943	47	27	production	production	NOUN
ajrhss-2943	47	28	,	,	PUNCT
ajrhss-2943	47	29	explaining	explain	VERB
ajrhss-2943	47	30	the	the	DET
ajrhss-2943	47	31	dominance	dominance	NOUN
ajrhss-2943	47	32	of	of	ADP
ajrhss-2943	47	33	th2	th2	PROPN
ajrhss-2943	47	34	helper	helper	NOUN
ajrhss-2943	47	35	cells	cell	NOUN
ajrhss-2943	47	36	in	in	ADP
ajrhss-2943	47	37	allergic	allergic	ADJ
ajrhss-2943	47	38	conditions	condition	NOUN
ajrhss-2943	47	39	[	[	X
ajrhss-2943	47	40	8	8	NUM
ajrhss-2943	47	41	]	]	PUNCT
ajrhss-2943	47	42	.	.	PUNCT
ajrhss-2943	48	1	ohashi	ohashi	PROPN
ajrhss-2943	48	2	et	et	PROPN
ajrhss-2943	48	3	al	al	PROPN
ajrhss-2943	48	4	.	.	PROPN
ajrhss-2943	48	5	reported	report	VERB
ajrhss-2943	48	6	no	no	DET
ajrhss-2943	48	7	significant	significant	ADJ
ajrhss-2943	48	8	difference	difference	NOUN
ajrhss-2943	48	9	in	in	ADP
ajrhss-2943	48	10	total	total	ADJ
ajrhss-2943	48	11	ige	ige	PROPN
ajrhss-2943	48	12	levels	level	NOUN
ajrhss-2943	48	13	among	among	ADP
ajrhss-2943	48	14	healthy	healthy	ADJ
ajrhss-2943	48	15	individuals	individual	NOUN
ajrhss-2943	48	16	,	,	PUNCT
ajrhss-2943	48	17	atopic	atopic	NOUN
ajrhss-2943	48	18	patients	patient	NOUN
ajrhss-2943	48	19	during	during	ADP
ajrhss-2943	48	20	clinical	clinical	ADJ
ajrhss-2943	48	21	symptoms	symptom	NOUN
ajrhss-2943	48	22	,	,	PUNCT
ajrhss-2943	48	23	and	and	CCONJ
ajrhss-2943	48	24	atopic	atopic	NOUN
ajrhss-2943	48	25	patients	patient	NOUN
ajrhss-2943	48	26	outside	outside	ADP
ajrhss-2943	48	27	clinical	clinical	ADJ
ajrhss-2943	48	28	periods	period	NOUN
ajrhss-2943	48	29	[	[	X
ajrhss-2943	48	30	10	10	NUM
ajrhss-2943	48	31	]	]	PUNCT
ajrhss-2943	48	32	.	.	PUNCT
ajrhss-2943	49	1	according	accord	VERB
ajrhss-2943	49	2	to	to	ADP
ajrhss-2943	49	3	finkelman	finkelman	PROPN
ajrhss-2943	49	4	et	et	PROPN
ajrhss-2943	49	5	al	al	PROPN
ajrhss-2943	49	6	.	.	PROPN
ajrhss-2943	49	7	,	,	PUNCT
ajrhss-2943	49	8	allergen	allergen	NOUN
ajrhss-2943	49	9	-	-	PUNCT
ajrhss-2943	49	10	specific	specific	ADJ
ajrhss-2943	49	11	ige	ige	NOUN
ajrhss-2943	49	12	levels	level	NOUN
ajrhss-2943	49	13	are	be	AUX
ajrhss-2943	49	14	more	more	ADV
ajrhss-2943	49	15	relevant	relevant	ADJ
ajrhss-2943	49	16	in	in	ADP
ajrhss-2943	49	17	allergic	allergic	ADJ
ajrhss-2943	49	18	diseases	disease	NOUN
ajrhss-2943	49	19	than	than	SCONJ
ajrhss-2943	49	20	total	total	ADJ
ajrhss-2943	49	21	ige	ige	PROPN
ajrhss-2943	49	22	.	.	PUNCT
ajrhss-2943	49	23	il4	il4	PROPN
ajrhss-2943	49	24	plays	play	VERB
ajrhss-2943	49	25	a	a	DET
ajrhss-2943	49	26	crucial	crucial	ADJ
ajrhss-2943	49	27	role	role	NOUN
ajrhss-2943	49	28	in	in	ADP
ajrhss-2943	49	29	inducing	induce	VERB
ajrhss-2943	49	30	and	and	CCONJ
ajrhss-2943	49	31	amplifying	amplifying	ADJ
ajrhss-2943	49	32	primary	primary	ADJ
ajrhss-2943	49	33	polyclonal	polyclonal	NOUN
ajrhss-2943	49	34	and	and	CCONJ
ajrhss-2943	49	35	secondary	secondary	ADJ
ajrhss-2943	49	36	ige	ige	PROPN
ajrhss-2943	49	37	responses	response	NOUN
ajrhss-2943	49	38	by	by	ADP
ajrhss-2943	49	39	b	b	NOUN
ajrhss-2943	49	40	lymphocytes	lymphocyte	NOUN
ajrhss-2943	49	41	[	[	X
ajrhss-2943	49	42	11	11	NUM
ajrhss-2943	49	43	]	]	PUNCT
ajrhss-2943	49	44	.	.	PUNCT
ajrhss-2943	50	1	li	li	PROPN
ajrhss-2943	50	2	et	et	PROPN
ajrhss-2943	50	3	al	al	PROPN
ajrhss-2943	50	4	.	.	PROPN
ajrhss-2943	50	5	demonstrated	demonstrate	VERB
ajrhss-2943	50	6	that	that	SCONJ
ajrhss-2943	50	7	nasal	nasal	PROPN
ajrhss-2943	50	8	lavage	lavage	NOUN
ajrhss-2943	50	9	fluid	fluid	NOUN
ajrhss-2943	50	10	from	from	ADP
ajrhss-2943	50	11	patients	patient	NOUN
ajrhss-2943	50	12	showed	show	VERB
ajrhss-2943	50	13	significantly	significantly	ADV
ajrhss-2943	50	14	elevated	elevated	ADJ
ajrhss-2943	50	15	levels	level	NOUN
ajrhss-2943	50	16	of	of	ADP
ajrhss-2943	50	17	both	both	CCONJ
ajrhss-2943	50	18	total	total	ADJ
ajrhss-2943	50	19	and	and	CCONJ
ajrhss-2943	50	20	specific	specific	ADJ
ajrhss-2943	50	21	ige	ige	NOUN
ajrhss-2943	50	22	compared	compare	VERB
ajrhss-2943	50	23	to	to	ADP
ajrhss-2943	50	24	healthy	healthy	ADJ
ajrhss-2943	50	25	controls	control	NOUN
ajrhss-2943	50	26	[	[	X
ajrhss-2943	50	27	12	12	NUM
ajrhss-2943	50	28	]	]	PUNCT
ajrhss-2943	50	29	.	.	PUNCT
ajrhss-2943	51	1	our	our	PRON
ajrhss-2943	51	2	study	study	NOUN
ajrhss-2943	51	3	did	do	AUX
ajrhss-2943	51	4	not	not	PART
ajrhss-2943	51	5	find	find	VERB
ajrhss-2943	51	6	statistically	statistically	ADV
ajrhss-2943	51	7	significant	significant	ADJ
ajrhss-2943	51	8	differences	difference	NOUN
ajrhss-2943	51	9	in	in	ADP
ajrhss-2943	51	10	serum	serum	NOUN
ajrhss-2943	51	11	total	total	NOUN
ajrhss-2943	51	12	ige	ige	PROPN
ajrhss-2943	51	13	between	between	ADP
ajrhss-2943	51	14	patients	patient	NOUN
ajrhss-2943	51	15	with	with	ADP
ajrhss-2943	51	16	ar	ar	NOUN
ajrhss-2943	51	17	and	and	CCONJ
ajrhss-2943	51	18	controls	control	NOUN
ajrhss-2943	51	19	,	,	PUNCT
ajrhss-2943	51	20	although	although	SCONJ
ajrhss-2943	51	21	approximately	approximately	ADV
ajrhss-2943	51	22	25	25	NUM
ajrhss-2943	51	23	%	%	NOUN
ajrhss-2943	51	24	of	of	ADP
ajrhss-2943	51	25	controls	control	NOUN
ajrhss-2943	51	26	had	have	VERB
ajrhss-2943	51	27	low	low	ADJ
ajrhss-2943	51	28	levels	level	NOUN
ajrhss-2943	51	29	of	of	ADP
ajrhss-2943	51	30	antibodies	antibody	NOUN
ajrhss-2943	51	31	.	.	PUNCT
ajrhss-2943	52	1	ohashi	ohashi	NOUN
ajrhss-2943	52	2	and	and	CCONJ
ajrhss-2943	52	3	colleagues	colleague	NOUN
ajrhss-2943	52	4	also	also	ADV
ajrhss-2943	52	5	studied	study	VERB
ajrhss-2943	52	6	il-4	il-4	PART
ajrhss-2943	52	7	involvement	involvement	NOUN
ajrhss-2943	52	8	in	in	ADP
ajrhss-2943	52	9	modulating	modulate	VERB
ajrhss-2943	52	10	atopic	atopic	NOUN
ajrhss-2943	52	11	responses	response	NOUN
ajrhss-2943	52	12	and	and	CCONJ
ajrhss-2943	52	13	treatment	treatment	NOUN
ajrhss-2943	52	14	effects	effect	NOUN
ajrhss-2943	52	15	,	,	PUNCT
ajrhss-2943	52	16	reporting	report	VERB
ajrhss-2943	52	17	decreased	decrease	VERB
ajrhss-2943	52	18	plasma	plasma	NOUN
ajrhss-2943	52	19	il-4	il-4	PART
ajrhss-2943	52	20	and	and	CCONJ
ajrhss-2943	52	21	ige	ige	PROPN
ajrhss-2943	52	22	concentrations	concentration	NOUN
ajrhss-2943	52	23	after	after	ADP
ajrhss-2943	52	24	subcutaneous	subcutaneous	ADJ
ajrhss-2943	52	25	immunotherapy	immunotherapy	NOUN
ajrhss-2943	52	26	in	in	ADP
ajrhss-2943	52	27	patients	patient	NOUN
ajrhss-2943	52	28	with	with	ADP
ajrhss-2943	52	29	ar	ar	NOUN
ajrhss-2943	52	30	[	[	X
ajrhss-2943	52	31	15	15	NUM
ajrhss-2943	52	32	]	]	PUNCT
ajrhss-2943	52	33	.	.	PUNCT
ajrhss-2943	53	1	other	other	ADJ
ajrhss-2943	53	2	authors	author	NOUN
ajrhss-2943	53	3	confirmed	confirm	VERB
ajrhss-2943	53	4	that	that	SCONJ
ajrhss-2943	53	5	immunotherapy	immunotherapy	NOUN
ajrhss-2943	53	6	reduces	reduce	VERB
ajrhss-2943	53	7	il-4	il-4	PRON
ajrhss-2943	53	8	and	and	CCONJ
ajrhss-2943	53	9	ige	ige	PROPN
ajrhss-2943	53	10	levels	level	NOUN
ajrhss-2943	53	11	regardless	regardless	ADV
ajrhss-2943	53	12	of	of	ADP
ajrhss-2943	53	13	clinical	clinical	ADJ
ajrhss-2943	53	14	symptom	symptom	NOUN
ajrhss-2943	53	15	severity	severity	NOUN
ajrhss-2943	53	16	[	[	X
ajrhss-2943	53	17	16,17	16,17	NUM
ajrhss-2943	53	18	]	]	PUNCT
ajrhss-2943	53	19	.	.	PUNCT
ajrhss-2943	54	1	our	our	PRON
ajrhss-2943	54	2	results	result	NOUN
ajrhss-2943	54	3	indicate	indicate	VERB
ajrhss-2943	54	4	elevated	elevated	ADJ
ajrhss-2943	54	5	serum	serum	NOUN
ajrhss-2943	54	6	il-4	il-4	X
ajrhss-2943	54	7	in	in	ADP
ajrhss-2943	54	8	ar	ar	NOUN
ajrhss-2943	54	9	patients	patient	NOUN
ajrhss-2943	54	10	compared	compare	VERB
ajrhss-2943	54	11	to	to	ADP
ajrhss-2943	54	12	controls	control	NOUN
ajrhss-2943	54	13	,	,	PUNCT
ajrhss-2943	54	14	with	with	ADP
ajrhss-2943	54	15	higher	high	ADJ
ajrhss-2943	54	16	levels	level	NOUN
ajrhss-2943	54	17	in	in	ADP
ajrhss-2943	54	18	seasonal	seasonal	ADJ
ajrhss-2943	54	19	ar	ar	NOUN
ajrhss-2943	54	20	than	than	ADP
ajrhss-2943	54	21	in	in	ADP
ajrhss-2943	54	22	persistent	persistent	ADJ
ajrhss-2943	54	23	ar	ar	NOUN
ajrhss-2943	54	24	patients	patient	NOUN
ajrhss-2943	54	25	,	,	PUNCT
ajrhss-2943	54	26	suggesting	suggest	VERB
ajrhss-2943	54	27	increased	increase	VERB
ajrhss-2943	54	28	inflammatory	inflammatory	ADJ
ajrhss-2943	54	29	activity	activity	NOUN
ajrhss-2943	54	30	driven	drive	VERB
ajrhss-2943	54	31	by	by	ADP
ajrhss-2943	54	32	pollen	pollen	NOUN
ajrhss-2943	54	33	allergens	allergen	NOUN
ajrhss-2943	54	34	.	.	PUNCT
ajrhss-2943	55	1	additionally	additionally	ADV
ajrhss-2943	55	2	,	,	PUNCT
ajrhss-2943	55	3	overweight	overweight	ADJ
ajrhss-2943	55	4	patients	patient	NOUN
ajrhss-2943	55	5	showed	show	VERB
ajrhss-2943	55	6	higher	high	ADJ
ajrhss-2943	55	7	il-4	il-4	NOUN
ajrhss-2943	55	8	levels	level	NOUN
ajrhss-2943	55	9	compared	compare	VERB
ajrhss-2943	55	10	to	to	ADP
ajrhss-2943	55	11	normal	normal	ADJ
ajrhss-2943	55	12	and	and	CCONJ
ajrhss-2943	55	13	underweight	underweight	NOUN
ajrhss-2943	55	14	subjects	subject	NOUN
ajrhss-2943	55	15	.	.	PUNCT
ajrhss-2943	56	1	several	several	ADJ
ajrhss-2943	56	2	studies	study	NOUN
ajrhss-2943	56	3	reported	report	VERB
ajrhss-2943	56	4	increased	increase	VERB
ajrhss-2943	56	5	il-4	il-4	NOUN
ajrhss-2943	57	1	and	and	CCONJ
ajrhss-2943	57	2	il-13	il-13	ADP
ajrhss-2943	57	3	in	in	ADP
ajrhss-2943	57	4	nasal	nasal	ADJ
ajrhss-2943	57	5	secretions	secretion	NOUN
ajrhss-2943	57	6	of	of	ADP
ajrhss-2943	57	7	patients	patient	NOUN
ajrhss-2943	57	8	with	with	ADP
ajrhss-2943	57	9	allergic	allergic	ADJ
ajrhss-2943	57	10	rhinitis	rhinitis	NOUN
ajrhss-2943	57	11	.	.	PUNCT
ajrhss-2943	58	1	for	for	ADP
ajrhss-2943	58	2	example	example	NOUN
ajrhss-2943	58	3	,	,	PUNCT
ajrhss-2943	58	4	scavuzzo	scavuzzo	VERB
ajrhss-2943	58	5	et	et	PROPN
ajrhss-2943	58	6	al	al	PROPN
ajrhss-2943	58	7	.	.	PROPN
ajrhss-2943	58	8	found	find	VERB
ajrhss-2943	58	9	significantly	significantly	ADV
ajrhss-2943	58	10	elevated	elevate	VERB
ajrhss-2943	58	11	il-4	il-4	PART
ajrhss-2943	58	12	levels	level	NOUN
ajrhss-2943	58	13	in	in	ADP
ajrhss-2943	58	14	ar	ar	NOUN
ajrhss-2943	58	15	patients	patient	NOUN
ajrhss-2943	58	16	compared	compare	VERB
ajrhss-2943	58	17	to	to	ADP
ajrhss-2943	58	18	healthy	healthy	ADJ
ajrhss-2943	58	19	individuals	individual	NOUN
ajrhss-2943	58	20	[	[	X
ajrhss-2943	58	21	19	19	NUM
ajrhss-2943	58	22	]	]	PUNCT
ajrhss-2943	58	23	.	.	PUNCT
ajrhss-2943	59	1	however	however	ADV
ajrhss-2943	59	2	,	,	PUNCT
ajrhss-2943	59	3	some	some	DET
ajrhss-2943	59	4	literature	literature	NOUN
ajrhss-2943	59	5	notes	note	VERB
ajrhss-2943	59	6	no	no	DET
ajrhss-2943	59	7	increase	increase	NOUN
ajrhss-2943	59	8	in	in	ADP
ajrhss-2943	59	9	il-4	il-4	NOUN
ajrhss-2943	59	10	,	,	PUNCT
ajrhss-2943	59	11	il-6	il-6	PRON
ajrhss-2943	59	12	,	,	PUNCT
ajrhss-2943	59	13	il-8	il-8	NOUN
ajrhss-2943	59	14	,	,	PUNCT
ajrhss-2943	59	15	leukotrienes	leukotrienes	NOUN
ajrhss-2943	59	16	c4	c4	NOUN
ajrhss-2943	59	17	,	,	PUNCT
ajrhss-2943	59	18	b4	b4	NOUN
ajrhss-2943	59	19	,	,	PUNCT
ajrhss-2943	59	20	and	and	CCONJ
ajrhss-2943	59	21	prostaglandin	prostaglandin	NOUN
ajrhss-2943	59	22	e2	e2	NOUN
ajrhss-2943	59	23	after	after	ADP
ajrhss-2943	59	24	two	two	NUM
ajrhss-2943	59	25	weeks	week	NOUN
ajrhss-2943	59	26	of	of	ADP
ajrhss-2943	59	27	intranasal	intranasal	ADJ
ajrhss-2943	59	28	corticosteroid	corticosteroid	NOUN
ajrhss-2943	59	29	therapy	therapy	NOUN
ajrhss-2943	59	30	,	,	PUNCT
ajrhss-2943	59	31	with	with	ADP
ajrhss-2943	59	32	changes	change	NOUN
ajrhss-2943	59	33	observed	observe	VERB
ajrhss-2943	59	34	only	only	ADV
ajrhss-2943	59	35	in	in	ADP
ajrhss-2943	59	36	eosinophil	eosinophil	ADJ
ajrhss-2943	59	37	counts	count	NOUN
ajrhss-2943	59	38	[	[	X
ajrhss-2943	59	39	11,12	11,12	NUM
ajrhss-2943	59	40	]	]	PUNCT
ajrhss-2943	59	41	.	.	PUNCT
ajrhss-2943	60	1	conclusion	conclusion	NOUN
ajrhss-2943	60	2	although	although	SCONJ
ajrhss-2943	60	3	significant	significant	ADJ
ajrhss-2943	60	4	differences	difference	NOUN
ajrhss-2943	60	5	in	in	ADP
ajrhss-2943	60	6	cytokine	cytokine	ADJ
ajrhss-2943	60	7	concentrations	concentration	NOUN
ajrhss-2943	60	8	were	be	AUX
ajrhss-2943	60	9	not	not	PART
ajrhss-2943	60	10	consistently	consistently	ADV
ajrhss-2943	60	11	observed	observe	VERB
ajrhss-2943	60	12	between	between	ADP
ajrhss-2943	60	13	groups	group	NOUN
ajrhss-2943	60	14	,	,	PUNCT
ajrhss-2943	60	15	our	our	PRON
ajrhss-2943	60	16	findings	finding	NOUN
ajrhss-2943	60	17	suggest	suggest	VERB
ajrhss-2943	60	18	that	that	SCONJ
ajrhss-2943	60	19	il-4	il-4	PRON
ajrhss-2943	60	20	and	and	CCONJ
ajrhss-2943	60	21	il-13	il-13	ADP
ajrhss-2943	60	22	serum	serum	NOUN
ajrhss-2943	60	23	levels	level	NOUN
ajrhss-2943	60	24	are	be	AUX
ajrhss-2943	60	25	elevated	elevate	VERB
ajrhss-2943	60	26	in	in	ADP
ajrhss-2943	60	27	patients	patient	NOUN
ajrhss-2943	60	28	with	with	ADP
ajrhss-2943	60	29	allergic	allergic	ADJ
ajrhss-2943	60	30	rhinitis	rhinitis	NOUN
ajrhss-2943	60	31	compared	compare	VERB
ajrhss-2943	60	32	to	to	ADP
ajrhss-2943	60	33	controls	control	NOUN
ajrhss-2943	60	34	.	.	PUNCT
ajrhss-2943	61	1	moreover	moreover	ADV
ajrhss-2943	61	2	,	,	PUNCT
ajrhss-2943	61	3	patients	patient	NOUN
ajrhss-2943	61	4	with	with	ADP
ajrhss-2943	61	5	seasonal	seasonal	ADJ
ajrhss-2943	61	6	allergic	allergic	ADJ
ajrhss-2943	61	7	rhinitis	rhinitis	NOUN
ajrhss-2943	61	8	exhibit	exhibit	VERB
ajrhss-2943	61	9	higher	high	ADJ
ajrhss-2943	61	10	cytokine	cytokine	ADJ
ajrhss-2943	61	11	american	american	ADJ
ajrhss-2943	61	12	journal	journal	PROPN
ajrhss-2943	61	13	of	of	ADP
ajrhss-2943	61	14	research	research	NOUN
ajrhss-2943	61	15	in	in	ADP
ajrhss-2943	61	16	humanities	humanity	NOUN
ajrhss-2943	61	17	and	and	CCONJ
ajrhss-2943	61	18	social	social	ADJ
ajrhss-2943	61	19	sciences	science	NOUN
ajrhss-2943	61	20	volume	volume	NOUN
ajrhss-2943	61	21	36	36	NUM
ajrhss-2943	61	22	may	may	PROPN
ajrhss-2943	61	23	2025	2025	NUM
ajrhss-2943	61	24	p	p	NOUN
ajrhss-2943	61	25	a	a	DET
ajrhss-2943	61	26	g	g	NOUN
ajrhss-2943	61	27	e	e	NOUN
ajrhss-2943	61	28	|	|	ADV
ajrhss-2943	61	29	74	74	NUM
ajrhss-2943	61	30	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-2943	61	31	concentrations	concentration	NOUN
ajrhss-2943	61	32	than	than	ADP
ajrhss-2943	61	33	those	those	PRON
ajrhss-2943	61	34	with	with	ADP
ajrhss-2943	61	35	persistent	persistent	ADJ
ajrhss-2943	61	36	forms	form	NOUN
ajrhss-2943	61	37	.	.	PUNCT
ajrhss-2943	62	1	overweight	overweight	ADJ
ajrhss-2943	62	2	patients	patient	NOUN
ajrhss-2943	62	3	also	also	ADV
ajrhss-2943	62	4	showed	show	VERB
ajrhss-2943	62	5	increased	increase	VERB
ajrhss-2943	62	6	il-4	il-4	NOUN
ajrhss-2943	62	7	levels	level	NOUN
ajrhss-2943	62	8	relative	relative	ADJ
ajrhss-2943	62	9	to	to	ADP
ajrhss-2943	62	10	normal	normal	ADJ
ajrhss-2943	62	11	and	and	CCONJ
ajrhss-2943	62	12	underweight	underweight	NOUN
ajrhss-2943	62	13	subjects	subject	NOUN
ajrhss-2943	62	14	.	.	PUNCT
ajrhss-2943	63	1	references	reference	NOUN
ajrhss-2943	63	2	:	:	PUNCT
ajrhss-2943	63	3	1	1	X
ajrhss-2943	63	4	.	.	PUNCT
ajrhss-2943	63	5	abdulkerimov	abdulkerimov	PROPN
ajrhss-2943	63	6	h.t	h.t	PROPN
ajrhss-2943	63	7	.	.	PROPN
ajrhss-2943	63	8	,	,	PUNCT
ajrhss-2943	63	9	garashhenko	garashhenko	PROPN
ajrhss-2943	63	10	t.i	t.i	PROPN
ajrhss-2943	63	11	.	.	PROPN
ajrhss-2943	63	12	,	,	PUNCT
ajrhss-2943	63	13	koshel	koshel	PROPN
ajrhss-2943	63	14	'	'	PART
ajrhss-2943	63	15	v.i	v.i	PROPN
ajrhss-2943	63	16	.	.	PROPN
ajrhss-2943	63	17	,	,	PUNCT
ajrhss-2943	63	18	ryazantsev	ryazantsev	PROPN
ajrhss-2943	63	19	s.v	s.v	PROPN
ajrhss-2943	63	20	.	.	PROPN
ajrhss-2943	63	21	,	,	PUNCT
ajrhss-2943	63	22	svistushkin	svistushkin	PROPN
ajrhss-2943	63	23	v.m	v.m	PROPN
ajrhss-2943	63	24	.	.	PUNCT
ajrhss-2943	63	25	(	(	PUNCT
ajrhss-2943	63	26	2013	2013	NUM
ajrhss-2943	63	27	)	)	PUNCT
ajrhss-2943	63	28	.	.	PUNCT
ajrhss-2943	64	1	principles	principle	NOUN
ajrhss-2943	64	2	of	of	ADP
ajrhss-2943	64	3	etiopathogenetic	etiopathogenetic	ADJ
ajrhss-2943	64	4	therapy	therapy	NOUN
ajrhss-2943	64	5	for	for	ADP
ajrhss-2943	64	6	acute	acute	PROPN
ajrhss-2943	64	7	rhinosinusitis	rhinosinusitis	PROPN
ajrhss-2943	64	8	.	.	PUNCT
ajrhss-2943	64	9	edited	edit	VERB
ajrhss-2943	64	10	by	by	ADP
ajrhss-2943	64	11	ryazantsev	ryazantsev	PROPN
ajrhss-2943	64	12	s.v	s.v	PROPN
ajrhss-2943	64	13	.	.	PROPN
ajrhss-2943	64	14	st	st	PROPN
ajrhss-2943	64	15	.	.	PROPN
ajrhss-2943	64	16	petersburg	petersburg	PROPN
ajrhss-2943	64	17	:	:	PUNCT
ajrhss-2943	64	18	poliforum	poliforum	PROPN
ajrhss-2943	64	19	group	group	NOUN
ajrhss-2943	64	20	.	.	PUNCT
ajrhss-2943	65	1	2	2	X
ajrhss-2943	65	2	.	.	X
ajrhss-2943	65	3	krivopalov	krivopalov	PROPN
ajrhss-2943	65	4	a.a	a.a	PROPN
ajrhss-2943	65	5	.	.	PROPN
ajrhss-2943	65	6	(	(	PUNCT
ajrhss-2943	65	7	2016	2016	NUM
ajrhss-2943	65	8	)	)	PUNCT
ajrhss-2943	65	9	.	.	PUNCT
ajrhss-2943	66	1	definitions	definition	NOUN
ajrhss-2943	66	2	,	,	PUNCT
ajrhss-2943	66	3	classification	classification	NOUN
ajrhss-2943	66	4	,	,	PUNCT
ajrhss-2943	66	5	etiology	etiology	NOUN
ajrhss-2943	66	6	,	,	PUNCT
ajrhss-2943	66	7	and	and	CCONJ
ajrhss-2943	66	8	epidemiology	epidemiology	NOUN
ajrhss-2943	66	9	of	of	ADP
ajrhss-2943	66	10	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	66	11	:	:	PUNCT
ajrhss-2943	66	12	a	a	DET
ajrhss-2943	66	13	literature	literature	NOUN
ajrhss-2943	66	14	review	review	NOUN
ajrhss-2943	66	15	.	.	PUNCT
ajrhss-2943	67	1	russian	russian	ADJ
ajrhss-2943	67	2	rhinology	rhinology	NOUN
ajrhss-2943	67	3	,	,	PUNCT
ajrhss-2943	67	4	(	(	PUNCT
ajrhss-2943	67	5	2	2	NUM
ajrhss-2943	67	6	)	)	PUNCT
ajrhss-2943	67	7	,	,	PUNCT
ajrhss-2943	67	8	39–45	39–45	NUM
ajrhss-2943	67	9	.	.	NOUN
ajrhss-2943	68	1	3	3	NUM
ajrhss-2943	68	2	.	.	X
ajrhss-2943	69	1	svistushkin	svistushkin	PROPN
ajrhss-2943	69	2	v.m	v.m	PROPN
ajrhss-2943	69	3	.	.	PROPN
ajrhss-2943	69	4	,	,	PUNCT
ajrhss-2943	69	5	grinev	grinev	PROPN
ajrhss-2943	69	6	i.a	i.a	PROPN
ajrhss-2943	69	7	.	.	PROPN
ajrhss-2943	69	8	,	,	PUNCT
ajrhss-2943	69	9	stecyuk	stecyuk	PROPN
ajrhss-2943	69	10	o.u	o.u	PROPN
ajrhss-2943	69	11	.	.	PROPN
ajrhss-2943	69	12	,	,	PUNCT
ajrhss-2943	69	13	andreeva	andreeva	VERB
ajrhss-2943	69	14	i.v	i.v	PROPN
ajrhss-2943	69	15	.	.	PUNCT
ajrhss-2943	70	1	(	(	PUNCT
ajrhss-2943	70	2	2015	2015	NUM
ajrhss-2943	70	3	)	)	PUNCT
ajrhss-2943	70	4	.	.	PUNCT
ajrhss-2943	71	1	recommendations	recommendation	NOUN
ajrhss-2943	71	2	for	for	ADP
ajrhss-2943	71	3	the	the	DET
ajrhss-2943	71	4	management	management	NOUN
ajrhss-2943	71	5	of	of	ADP
ajrhss-2943	71	6	adult	adult	NOUN
ajrhss-2943	71	7	patients	patient	NOUN
ajrhss-2943	71	8	with	with	ADP
ajrhss-2943	71	9	acute	acute	PROPN
ajrhss-2943	71	10	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	71	11	.	.	PUNCT
ajrhss-2943	72	1	treating	treat	VERB
ajrhss-2943	72	2	physician	physician	NOUN
ajrhss-2943	72	3	,	,	PUNCT
ajrhss-2943	72	4	(	(	PUNCT
ajrhss-2943	72	5	11	11	NUM
ajrhss-2943	72	6	)	)	PUNCT
ajrhss-2943	72	7	,	,	PUNCT
ajrhss-2943	72	8	90–96	90–96	NUM
ajrhss-2943	72	9	.	.	NOUN
ajrhss-2943	73	1	4	4	NUM
ajrhss-2943	73	2	.	.	X
ajrhss-2943	73	3	piskunov	piskunov	PROPN
ajrhss-2943	73	4	s.z	s.z	PROPN
ajrhss-2943	73	5	.	.	PROPN
ajrhss-2943	73	6	,	,	PUNCT
ajrhss-2943	73	7	piskunov	piskunov	PROPN
ajrhss-2943	73	8	g.z	g.z	PROPN
ajrhss-2943	73	9	.	.	PROPN
ajrhss-2943	74	1	(	(	PUNCT
ajrhss-2943	74	2	2013	2013	NUM
ajrhss-2943	74	3	)	)	PUNCT
ajrhss-2943	74	4	.	.	PUNCT
ajrhss-2943	75	1	rhinosinusitis	rhinosinusitis	PROPN
ajrhss-2943	75	2	.	.	PUNCT
ajrhss-2943	76	1	moscow	moscow	PROPN
ajrhss-2943	76	2	:	:	PUNCT
ajrhss-2943	76	3	mia	mia	PROPN
ajrhss-2943	76	4	publishing	publishing	PROPN
ajrhss-2943	76	5	.	.	PUNCT
ajrhss-2943	77	1	5	5	X
ajrhss-2943	77	2	.	.	X
ajrhss-2943	77	3	kamanin	kamanin	PROPN
ajrhss-2943	77	4	e.i	e.i	PROPN
ajrhss-2943	77	5	.	.	PROPN
ajrhss-2943	77	6	,	,	PUNCT
ajrhss-2943	77	7	kozlov	kozlov	PROPN
ajrhss-2943	77	8	r.s	r.s	PROPN
ajrhss-2943	77	9	.	.	PROPN
ajrhss-2943	77	10	,	,	PUNCT
ajrhss-2943	77	11	veselov	veselov	NOUN
ajrhss-2943	77	12	a.v	a.v	PROPN
ajrhss-2943	77	13	.	.	PROPN
ajrhss-2943	77	14	(	(	PUNCT
ajrhss-2943	77	15	2018	2018	NUM
ajrhss-2943	77	16	)	)	PUNCT
ajrhss-2943	77	17	.	.	PUNCT
ajrhss-2943	78	1	acute	acute	VERB
ajrhss-2943	78	2	bacterial	bacterial	ADJ
ajrhss-2943	78	3	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	78	4	.	.	PUNCT
ajrhss-2943	79	1	clinical	clinical	ADJ
ajrhss-2943	79	2	microbiology	microbiology	NOUN
ajrhss-2943	79	3	and	and	CCONJ
ajrhss-2943	79	4	antimicrobial	antimicrobial	ADJ
ajrhss-2943	79	5	chemotherapy	chemotherapy	NOUN
ajrhss-2943	79	6	,	,	PUNCT
ajrhss-2943	79	7	(	(	PUNCT
ajrhss-2943	79	8	1	1	NUM
ajrhss-2943	79	9	)	)	PUNCT
ajrhss-2943	79	10	,	,	PUNCT
ajrhss-2943	79	11	44–54	44–54	NUM
ajrhss-2943	79	12	.	.	PUNCT
ajrhss-2943	80	1	6	6	NUM
ajrhss-2943	80	2	.	.	X
ajrhss-2943	80	3	turovsky	turovsky	NOUN
ajrhss-2943	80	4	a.b	a.b	PROPN
ajrhss-2943	80	5	.	.	PROPN
ajrhss-2943	80	6	,	,	PUNCT
ajrhss-2943	80	7	kondrashkina	kondrashkina	PROPN
ajrhss-2943	80	8	v.v	v.v	PROPN
ajrhss-2943	80	9	.	.	PROPN
ajrhss-2943	80	10	(	(	PUNCT
ajrhss-2943	80	11	2013	2013	NUM
ajrhss-2943	80	12	)	)	PUNCT
ajrhss-2943	80	13	.	.	PUNCT
ajrhss-2943	81	1	acute	acute	ADJ
ajrhss-2943	81	2	bacterial	bacterial	ADJ
ajrhss-2943	81	3	sinusitis	sinusitis	NOUN
ajrhss-2943	81	4	:	:	PUNCT
ajrhss-2943	81	5	problems	problem	NOUN
ajrhss-2943	81	6	and	and	CCONJ
ajrhss-2943	81	7	solutions	solution	NOUN
ajrhss-2943	81	8	.	.	PUNCT
ajrhss-2943	82	1	russian	russian	ADJ
ajrhss-2943	82	2	medical	medical	ADJ
ajrhss-2943	82	3	journal	journal	PROPN
ajrhss-2943	82	4	,	,	PUNCT
ajrhss-2943	82	5	(	(	PUNCT
ajrhss-2943	82	6	11	11	NUM
ajrhss-2943	82	7	)	)	PUNCT
ajrhss-2943	82	8	,	,	PUNCT
ajrhss-2943	82	9	549–552	549–552	NUM
ajrhss-2943	82	10	.	.	PUNCT
ajrhss-2943	83	1	7	7	NUM
ajrhss-2943	83	2	.	.	X
ajrhss-2943	84	1	meltzer	meltzer	PROPN
ajrhss-2943	84	2	e.o	e.o	PROPN
ajrhss-2943	84	3	.	.	PROPN
ajrhss-2943	84	4	,	,	PUNCT
ajrhss-2943	84	5	hamilos	hamilos	PROPN
ajrhss-2943	84	6	d.l	d.l	PROPN
ajrhss-2943	84	7	.	.	PROPN
ajrhss-2943	84	8	,	,	PUNCT
ajrhss-2943	84	9	hadley	hadley	PROPN
ajrhss-2943	84	10	j.a	j.a	PROPN
ajrhss-2943	84	11	.	.	PROPN
ajrhss-2943	84	12	,	,	PUNCT
ajrhss-2943	84	13	lanza	lanza	PROPN
ajrhss-2943	84	14	d.	d.	PROPN
ajrhss-2943	84	15	,	,	PUNCT
ajrhss-2943	84	16	marple	marple	PROPN
ajrhss-2943	84	17	b.f	b.f	PROPN
ajrhss-2943	84	18	.	.	PROPN
ajrhss-2943	84	19	,	,	PUNCT
ajrhss-2943	84	20	nicklas	nicklas	PROPN
ajrhss-2943	84	21	r.a	r.a	PROPN
ajrhss-2943	84	22	.	.	PROPN
ajrhss-2943	84	23	,	,	PUNCT
ajrhss-2943	84	24	bachert	bachert	PROPN
ajrhss-2943	84	25	c.	c.	PROPN
ajrhss-2943	84	26	(	(	PUNCT
ajrhss-2943	84	27	2014	2014	NUM
ajrhss-2943	84	28	)	)	PUNCT
ajrhss-2943	84	29	.	.	PUNCT
ajrhss-2943	85	1	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	85	2	:	:	PUNCT
ajrhss-2943	85	3	establishing	establish	VERB
ajrhss-2943	85	4	definitions	definition	NOUN
ajrhss-2943	85	5	for	for	ADP
ajrhss-2943	85	6	clinical	clinical	ADJ
ajrhss-2943	85	7	research	research	NOUN
ajrhss-2943	85	8	and	and	CCONJ
ajrhss-2943	85	9	patient	patient	ADJ
ajrhss-2943	85	10	care	care	NOUN
ajrhss-2943	85	11	.	.	PUNCT
ajrhss-2943	86	1	otolaryngology	otolaryngology	NOUN
ajrhss-2943	86	2	–	–	PUNCT
ajrhss-2943	86	3	head	head	NOUN
ajrhss-2943	86	4	and	and	CCONJ
ajrhss-2943	86	5	neck	neck	NOUN
ajrhss-2943	86	6	surgery	surgery	NOUN
ajrhss-2943	86	7	,	,	PUNCT
ajrhss-2943	86	8	114	114	NUM
ajrhss-2943	86	9	,	,	PUNCT
ajrhss-2943	86	10	155–212	155–212	NUM
ajrhss-2943	86	11	.	.	NOUN
ajrhss-2943	86	12	8	8	NUM
ajrhss-2943	86	13	.	.	PUNCT
ajrhss-2943	87	1	thomas	thomas	PROPN
ajrhss-2943	87	2	m.	m.	PROPN
ajrhss-2943	87	3	,	,	PUNCT
ajrhss-2943	87	4	yawn	yawn	PROPN
ajrhss-2943	87	5	b.p	b.p	PROPN
ajrhss-2943	87	6	.	.	PROPN
ajrhss-2943	87	7	,	,	PUNCT
ajrhss-2943	87	8	price	price	NOUN
ajrhss-2943	87	9	d.	d.	PROPN
ajrhss-2943	87	10	,	,	PUNCT
ajrhss-2943	87	11	lund	lund	PROPN
ajrhss-2943	87	12	v.	v.	PROPN
ajrhss-2943	87	13	,	,	PUNCT
ajrhss-2943	87	14	mullol	mullol	PROPN
ajrhss-2943	87	15	j.	j.	PROPN
ajrhss-2943	87	16	,	,	PUNCT
ajrhss-2943	87	17	fokkens	fokken	VERB
ajrhss-2943	87	18	w.	w.	PROPN
ajrhss-2943	87	19	(	(	PUNCT
ajrhss-2943	87	20	2014	2014	NUM
ajrhss-2943	87	21	)	)	PUNCT
ajrhss-2943	87	22	.	.	PUNCT
ajrhss-2943	88	1	european	european	ADJ
ajrhss-2943	88	2	position	position	NOUN
ajrhss-2943	88	3	paper	paper	NOUN
ajrhss-2943	88	4	on	on	ADP
ajrhss-2943	88	5	rhinosinusitis	rhinosinusitis	PROPN
ajrhss-2943	88	6	and	and	CCONJ
ajrhss-2943	88	7	nasal	nasal	PROPN
ajrhss-2943	88	8	polyps	polyp	NOUN
ajrhss-2943	88	9	group	group	NOUN
ajrhss-2943	88	10	.	.	PUNCT
ajrhss-2943	89	1	primary	primary	ADJ
ajrhss-2943	89	2	care	care	NOUN
ajrhss-2943	89	3	respiratory	respiratory	ADJ
ajrhss-2943	89	4	journal	journal	NOUN
ajrhss-2943	89	5	,	,	PUNCT
ajrhss-2943	89	6	17	17	NUM
ajrhss-2943	89	7	,	,	PUNCT
ajrhss-2943	89	8	79–89	79–89	NUM
ajrhss-2943	89	9	.	.	NOUN
ajrhss-2943	89	10	9	9	NUM
ajrhss-2943	89	11	.	.	X
ajrhss-2943	90	1	meltzer	meltzer	PROPN
ajrhss-2943	90	2	e.o	e.o	PROPN
ajrhss-2943	90	3	.	.	PROPN
ajrhss-2943	90	4	,	,	PUNCT
ajrhss-2943	90	5	hamilos	hamilos	PROPN
ajrhss-2943	90	6	d.l	d.l	PROPN
ajrhss-2943	90	7	.	.	PROPN
ajrhss-2943	90	8	(	(	PUNCT
ajrhss-2943	90	9	2014	2014	NUM
ajrhss-2943	90	10	)	)	PUNCT
ajrhss-2943	90	11	.	.	PUNCT
ajrhss-2943	91	1	rhinosinusitis	rhinosinusitis	ADJ
ajrhss-2943	91	2	diagnosis	diagnosis	NOUN
ajrhss-2943	91	3	and	and	CCONJ
ajrhss-2943	91	4	management	management	NOUN
ajrhss-2943	91	5	for	for	ADP
ajrhss-2943	91	6	clinicians	clinician	NOUN
ajrhss-2943	91	7	:	:	PUNCT
ajrhss-2943	91	8	a	a	DET
ajrhss-2943	91	9	summary	summary	NOUN
ajrhss-2943	91	10	of	of	ADP
ajrhss-2943	91	11	recent	recent	ADJ
ajrhss-2943	91	12	consensus	consensus	NOUN
ajrhss-2943	91	13	guidelines	guideline	NOUN
ajrhss-2943	91	14	.	.	PUNCT
ajrhss-2943	92	1	mayo	mayo	PROPN
ajrhss-2943	92	2	clinic	clinic	PROPN
ajrhss-2943	92	3	proceedings	proceeding	NOUN
ajrhss-2943	92	4	,	,	PUNCT
ajrhss-2943	92	5	86	86	NUM
ajrhss-2943	92	6	,	,	PUNCT
ajrhss-2943	92	7	427–443	427–443	NUM
ajrhss-2943	92	8	.	.	PUNCT
ajrhss-2943	93	1	10	10	NUM
ajrhss-2943	93	2	.	.	X
ajrhss-2943	93	3	chow	chow	PROPN
ajrhss-2943	93	4	a.w	a.w	PROPN
ajrhss-2943	93	5	.	.	PROPN
ajrhss-2943	93	6	,	,	PUNCT
ajrhss-2943	93	7	benninger	benninger	PROPN
ajrhss-2943	93	8	m.s	m.s	PROPN
ajrhss-2943	93	9	.	.	PROPN
ajrhss-2943	93	10	,	,	PUNCT
ajrhss-2943	93	11	brook	brook	PROPN
ajrhss-2943	93	12	i.	i.	PROPN
ajrhss-2943	93	13	,	,	PUNCT
ajrhss-2943	93	14	brozek	brozek	PROPN
ajrhss-2943	93	15	j.l	j.l	PROPN
ajrhss-2943	93	16	.	.	PROPN
ajrhss-2943	93	17	(	(	PUNCT
ajrhss-2943	93	18	2012	2012	NUM
ajrhss-2943	93	19	)	)	PUNCT
ajrhss-2943	93	20	.	.	PUNCT
ajrhss-2943	94	1	infectious	infectious	ADJ
ajrhss-2943	94	2	diseases	disease	NOUN
ajrhss-2943	94	3	society	society	NOUN
ajrhss-2943	94	4	of	of	ADP
ajrhss-2943	94	5	america	america	PROPN
ajrhss-2943	94	6	clinical	clinical	ADJ
ajrhss-2943	94	7	practice	practice	NOUN
ajrhss-2943	94	8	guideline	guideline	NOUN
ajrhss-2943	94	9	for	for	ADP
ajrhss-2943	94	10	acute	acute	ADJ
ajrhss-2943	94	11	bacterial	bacterial	ADJ
ajrhss-2943	94	12	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	94	13	in	in	ADP
ajrhss-2943	94	14	children	child	NOUN
ajrhss-2943	94	15	and	and	CCONJ
ajrhss-2943	94	16	adults	adult	NOUN
ajrhss-2943	94	17	.	.	PUNCT
ajrhss-2943	95	1	clinical	clinical	ADJ
ajrhss-2943	95	2	infectious	infectious	ADJ
ajrhss-2943	95	3	diseases	disease	NOUN
ajrhss-2943	95	4	,	,	PUNCT
ajrhss-2943	95	5	54	54	NUM
ajrhss-2943	95	6	,	,	PUNCT
ajrhss-2943	95	7	72–112	72–112	NUM
ajrhss-2943	95	8	.	.	NOUN
ajrhss-2943	95	9	11	11	NUM
ajrhss-2943	95	10	.	.	X
ajrhss-2943	96	1	fokkens	fokkens	PROPN
ajrhss-2943	96	2	w.j	w.j	PROPN
ajrhss-2943	96	3	.	.	PROPN
ajrhss-2943	96	4	,	,	PUNCT
ajrhss-2943	96	5	lund	lund	PROPN
ajrhss-2943	96	6	v.j	v.j	PROPN
ajrhss-2943	96	7	.	.	PROPN
ajrhss-2943	96	8	,	,	PUNCT
ajrhss-2943	96	9	mullol	mullol	PROPN
ajrhss-2943	96	10	j.	j.	PROPN
ajrhss-2943	96	11	,	,	PUNCT
ajrhss-2943	96	12	bachert	bachert	PROPN
ajrhss-2943	96	13	c.	c.	PROPN
ajrhss-2943	96	14	,	,	PUNCT
ajrhss-2943	96	15	alobid	alobid	ADJ
ajrhss-2943	96	16	i.	i.	PROPN
ajrhss-2943	96	17	,	,	PUNCT
ajrhss-2943	96	18	baroody	baroody	PROPN
ajrhss-2943	96	19	f.	f.	PROPN
ajrhss-2943	96	20	(	(	PUNCT
ajrhss-2943	96	21	2012	2012	NUM
ajrhss-2943	96	22	)	)	PUNCT
ajrhss-2943	96	23	.	.	PUNCT
ajrhss-2943	97	1	european	european	ADJ
ajrhss-2943	97	2	position	position	NOUN
ajrhss-2943	97	3	paper	paper	NOUN
ajrhss-2943	97	4	on	on	ADP
ajrhss-2943	97	5	rhinosinusitis	rhinosinusitis	PROPN
ajrhss-2943	97	6	and	and	CCONJ
ajrhss-2943	97	7	nasal	nasal	ADJ
ajrhss-2943	97	8	polyps	polyp	NOUN
ajrhss-2943	97	9	2012	2012	NUM
ajrhss-2943	97	10	:	:	PUNCT
ajrhss-2943	97	11	summary	summary	NOUN
ajrhss-2943	97	12	for	for	ADP
ajrhss-2943	97	13	otorhinolaryngologists	otorhinolaryngologist	NOUN
ajrhss-2943	97	14	.	.	PUNCT
ajrhss-2943	98	1	rhinology	rhinology	NOUN
ajrhss-2943	98	2	,	,	PUNCT
ajrhss-2943	98	3	50	50	NUM
ajrhss-2943	98	4	,	,	PUNCT
ajrhss-2943	98	5	1–12	1–12	NOUN
ajrhss-2943	98	6	.	.	PUNCT
ajrhss-2943	99	1	12	12	NUM
ajrhss-2943	99	2	.	.	PUNCT
ajrhss-2943	100	1	kern	kern	PROPN
ajrhss-2943	100	2	rc	rc	PROPN
ajrhss-2943	100	3	.	.	PROPN
ajrhss-2943	100	4	perspectives	perspective	NOUN
ajrhss-2943	100	5	on	on	ADP
ajrhss-2943	100	6	the	the	DET
ajrhss-2943	100	7	etiology	etiology	NOUN
ajrhss-2943	100	8	of	of	ADP
ajrhss-2943	100	9	chronic	chronic	ADJ
ajrhss-2943	100	10	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	100	11	:	:	PUNCT
ajrhss-2943	100	12	an	an	DET
ajrhss-2943	100	13	immune	immune	ADJ
ajrhss-2943	100	14	barrier	barrier	NOUN
ajrhss-2943	100	15	hypothesis	hypothesis	NOUN
ajrhss-2943	100	16	.	.	PUNCT
ajrhss-2943	101	1	am	be	AUX
ajrhss-2943	101	2	j	j	PROPN
ajrhss-2943	101	3	rhinol	rhinol	NOUN
ajrhss-2943	101	4	.	.	PUNCT
ajrhss-2943	102	1	2018;22:549	2018;22:549	PROPN
ajrhss-2943	102	2	-	-	PUNCT
ajrhss-2943	102	3	559	559	NUM
ajrhss-2943	102	4	.	.	PUNCT
ajrhss-2943	103	1	13	13	NUM
ajrhss-2943	103	2	.	.	PUNCT
ajrhss-2943	103	3	harvey	harvey	PROPN
ajrhss-2943	103	4	r.	r.	PROPN
ajrhss-2943	103	5	nasal	nasal	PROPN
ajrhss-2943	103	6	saline	saline	VERB
ajrhss-2943	103	7	irrigations	irrigation	NOUN
ajrhss-2943	103	8	for	for	ADP
ajrhss-2943	103	9	the	the	DET
ajrhss-2943	103	10	symptoms	symptom	NOUN
ajrhss-2943	103	11	of	of	ADP
ajrhss-2943	103	12	chronic	chronic	ADJ
ajrhss-2943	103	13	rhinosinusitis	rhinosinusitis	NOUN
ajrhss-2943	103	14	.	.	PUNCT
ajrhss-2943	104	1	cochrane	cochrane	PROPN
ajrhss-2943	104	2	database	database	PROPN
ajrhss-2943	104	3	syst	syst	PROPN
ajrhss-2943	104	4	rev	rev	PROPN
ajrhss-2943	104	5	.	.	PROPN
ajrhss-2943	105	1	2017;18	2017;18	NUM
ajrhss-2943	105	2	.	.	PROPN
ajrhss-2943	105	3	14	14	NUM
ajrhss-2943	105	4	.	.	PUNCT
ajrhss-2943	106	1	fineman	fineman	PROPN
ajrhss-2943	106	2	sm	sm	PROPN
ajrhss-2943	106	3	.	.	PUNCT
ajrhss-2943	107	1	the	the	DET
ajrhss-2943	107	2	burden	burden	NOUN
ajrhss-2943	107	3	of	of	ADP
ajrhss-2943	107	4	allergic	allergic	ADJ
ajrhss-2943	107	5	rhinitis	rhinitis	NOUN
ajrhss-2943	107	6	:	:	PUNCT
ajrhss-2943	107	7	beyond	beyond	ADP
ajrhss-2943	107	8	dollars	dollar	NOUN
ajrhss-2943	107	9	and	and	CCONJ
ajrhss-2943	107	10	cents	cent	NOUN
ajrhss-2943	107	11	.	.	PUNCT
ajrhss-2943	108	1	ann	ann	PROPN
ajrhss-2943	108	2	allergy	allergy	PROPN
ajrhss-2943	108	3	asthma	asthma	PROPN
ajrhss-2943	108	4	immunol	immunol	PROPN
ajrhss-2943	108	5	.	.	PUNCT
ajrhss-2943	109	1	2002;88:2–7	2002;88:2–7	NUM
ajrhss-2943	109	2	.	.	PUNCT
ajrhss-2943	110	1	15	15	NUM
ajrhss-2943	110	2	.	.	PUNCT
ajrhss-2943	111	1	ouraishi	ouraishi	PROPN
ajrhss-2943	111	2	sa	sa	PROPN
ajrhss-2943	111	3	,	,	PUNCT
ajrhss-2943	111	4	davies	davies	PROPN
ajrhss-2943	111	5	mj	mj	PROPN
ajrhss-2943	111	6	,	,	PUNCT
ajrhss-2943	111	7	craig	craig	PROPN
ajrhss-2943	111	8	tj	tj	PROPN
ajrhss-2943	111	9	.	.	PUNCT
ajrhss-2943	111	10	inflammatory	inflammatory	ADJ
ajrhss-2943	111	11	responses	response	NOUN
ajrhss-2943	111	12	in	in	ADP
ajrhss-2943	111	13	allergic	allergic	ADJ
ajrhss-2943	111	14	rhinitis	rhinitis	NOUN
ajrhss-2943	111	15	:	:	PUNCT
ajrhss-2943	111	16	traditional	traditional	ADJ
ajrhss-2943	111	17	approaches	approach	NOUN
ajrhss-2943	111	18	and	and	CCONJ
ajrhss-2943	111	19	novel	novel	ADJ
ajrhss-2943	111	20	treatment	treatment	NOUN
ajrhss-2943	111	21	strategies	strategy	NOUN
ajrhss-2943	111	22	.	.	PUNCT
ajrhss-2943	112	1	j	j	PROPN
ajrhss-2943	112	2	am	be	AUX
ajrhss-2943	112	3	osteopath	osteopath	NOUN
ajrhss-2943	112	4	assoc	assoc	NOUN
ajrhss-2943	112	5	.	.	PUNCT
ajrhss-2943	113	1	2004;104	2004;104	NUM
ajrhss-2943	113	2	:	:	PUNCT
ajrhss-2943	113	3	s7	s7	NOUN
ajrhss-2943	113	4	–	–	PUNCT
ajrhss-2943	113	5	s15	s15	NOUN
ajrhss-2943	113	6	.	.	PUNCT
ajrhss-2943	114	1	16	16	NUM
ajrhss-2943	114	2	.	.	PUNCT
ajrhss-2943	115	1	lipworth	lipworth	NOUN
ajrhss-2943	115	2	bj	bj	NOUN
ajrhss-2943	115	3	.	.	PUNCT
ajrhss-2943	116	1	emerging	emerge	VERB
ajrhss-2943	116	2	role	role	NOUN
ajrhss-2943	116	3	of	of	ADP
ajrhss-2943	116	4	antileukotriene	antileukotriene	NOUN
ajrhss-2943	116	5	therapy	therapy	NOUN
ajrhss-2943	116	6	in	in	ADP
ajrhss-2943	116	7	allergic	allergic	ADJ
ajrhss-2943	116	8	rhinitis	rhinitis	NOUN
ajrhss-2943	116	9	.	.	PUNCT
ajrhss-2943	117	1	clin	clin	PROPN
ajrhss-2943	117	2	exp	exp	PROPN
ajrhss-2943	117	3	allergy	allergy	PROPN
ajrhss-2943	117	4	.	.	PUNCT
ajrhss-2943	118	1	2001;31:1813–1821	2001;31:1813–1821	PROPN
ajrhss-2943	118	2	.	.	PUNCT
ajrhss-2943	119	1	17	17	NUM
ajrhss-2943	119	2	.	.	PUNCT
ajrhss-2943	120	1	ciebiada	ciebiada	PROPN
ajrhss-2943	120	2	m	m	PROPN
ajrhss-2943	120	3	,	,	PUNCT
ajrhss-2943	120	4	gorska	gorska	NOUN
ajrhss-2943	120	5	-	-	PUNCT
ajrhss-2943	120	6	ciebiada	ciebiada	NOUN
ajrhss-2943	120	7	m	m	PROPN
ajrhss-2943	120	8	,	,	PUNCT
ajrhss-2943	120	9	dubuske	dubuske	PROPN
ajrhss-2943	120	10	lm	lm	PROPN
ajrhss-2943	120	11	,	,	PUNCT
ajrhss-2943	120	12	gorski	gorski	ADJ
ajrhss-2943	120	13	p.	p.	PROPN
ajrhss-2943	120	14	montelukast	montelukast	NOUN
ajrhss-2943	120	15	with	with	ADP
ajrhss-2943	120	16	desloratadine	desloratadine	NOUN
ajrhss-2943	120	17	or	or	CCONJ
ajrhss-2943	120	18	levocetirizine	levocetirizine	ADJ
ajrhss-2943	120	19	for	for	ADP
ajrhss-2943	120	20	the	the	DET
ajrhss-2943	120	21	treatment	treatment	NOUN
ajrhss-2943	120	22	of	of	ADP
ajrhss-2943	120	23	persistent	persistent	ADJ
ajrhss-2943	120	24	allergic	allergic	ADJ
ajrhss-2943	120	25	rhinitis	rhinitis	NOUN
ajrhss-2943	120	26	.	.	PUNCT
ajrhss-2943	121	1	ann	ann	PROPN
ajrhss-2943	121	2	allergy	allergy	PROPN
ajrhss-2943	121	3	asthma	asthma	PROPN
ajrhss-2943	121	4	immunol	immunol	PROPN
ajrhss-2943	121	5	.	.	PUNCT
ajrhss-2943	122	1	2006;97:664–671	2006;97:664–671	PROPN
ajrhss-2943	122	2	.	.	PUNCT
ajrhss-2943	122	3	american	american	PROPN
ajrhss-2943	122	4	journal	journal	PROPN
ajrhss-2943	122	5	of	of	ADP
ajrhss-2943	122	6	research	research	NOUN
ajrhss-2943	122	7	in	in	ADP
ajrhss-2943	122	8	humanities	humanity	NOUN
ajrhss-2943	122	9	and	and	CCONJ
ajrhss-2943	122	10	social	social	ADJ
ajrhss-2943	122	11	sciences	science	NOUN
ajrhss-2943	122	12	volume	volume	NOUN
ajrhss-2943	122	13	36	36	NUM
ajrhss-2943	122	14	may	may	PROPN
ajrhss-2943	122	15	2025	2025	NUM
ajrhss-2943	122	16	p	p	NOUN
ajrhss-2943	122	17	a	a	DET
ajrhss-2943	122	18	g	g	NOUN
ajrhss-2943	122	19	e	e	NOUN
ajrhss-2943	123	1	|	|	ADV
ajrhss-2943	123	2	75	75	NUM
ajrhss-2943	123	3	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-2943	123	4	18	18	NUM
ajrhss-2943	123	5	.	.	PUNCT
ajrhss-2943	124	1	wilson	wilson	PROPN
ajrhss-2943	124	2	am	be	AUX
ajrhss-2943	124	3	,	,	PUNCT
ajrhss-2943	124	4	orr	orr	PROPN
ajrhss-2943	124	5	lc	lc	PROPN
ajrhss-2943	124	6	,	,	PUNCT
ajrhss-2943	124	7	coutie	coutie	PROPN
ajrhss-2943	124	8	wj	wj	PROPN
ajrhss-2943	124	9	,	,	PUNCT
ajrhss-2943	124	10	sims	sim	NOUN
ajrhss-2943	124	11	ej	ej	PROPN
ajrhss-2943	124	12	,	,	PUNCT
ajrhss-2943	124	13	lipworth	lipworth	NOUN
ajrhss-2943	124	14	bj	bj	NOUN
ajrhss-2943	124	15	.	.	PUNCT
ajrhss-2943	125	1	a	a	DET
ajrhss-2943	125	2	comparison	comparison	NOUN
ajrhss-2943	125	3	of	of	ADP
ajrhss-2943	125	4	once	once	ADV
ajrhss-2943	125	5	daily	daily	ADJ
ajrhss-2943	125	6	fexofenadine	fexofenadine	NOUN
ajrhss-2943	125	7	versus	versus	ADP
ajrhss-2943	125	8	the	the	DET
ajrhss-2943	125	9	combination	combination	NOUN
ajrhss-2943	125	10	of	of	ADP
ajrhss-2943	125	11	montelukast	montelukast	NOUN
ajrhss-2943	125	12	plus	plus	CCONJ
ajrhss-2943	125	13	loratadine	loratadine	NOUN
ajrhss-2943	125	14	on	on	ADP
ajrhss-2943	125	15	domiciliary	domiciliary	PROPN
ajrhss-2943	125	16	nasal	nasal	PROPN
ajrhss-2943	125	17	peak	peak	PROPN
ajrhss-2943	125	18	flow	flow	NOUN
ajrhss-2943	125	19	and	and	CCONJ
ajrhss-2943	125	20	symptoms	symptom	NOUN
ajrhss-2943	125	21	in	in	ADP
ajrhss-2943	125	22	seasonal	seasonal	ADJ
ajrhss-2943	125	23	allergic	allergic	ADJ
ajrhss-2943	125	24	rhinitis	rhinitis	NOUN
ajrhss-2943	125	25	.	.	PUNCT
ajrhss-2943	126	1	clin	clin	PROPN
ajrhss-2943	126	2	exp	exp	PROPN
ajrhss-2943	126	3	allergy	allergy	PROPN
ajrhss-2943	126	4	.	.	PUNCT
ajrhss-2943	127	1	2002;32:126–132	2002;32:126–132	X
ajrhss-2943	127	2	.	.	PROPN
ajrhss-2943	127	3	19	19	NUM
ajrhss-2943	127	4	.	.	PUNCT
ajrhss-2943	128	1	bousquet	bousquet	PROPN
ajrhss-2943	128	2	j	j	PROPN
ajrhss-2943	128	3	,	,	PUNCT
ajrhss-2943	128	4	van	van	PROPN
ajrhss-2943	128	5	cauwenberge	cauwenberge	NOUN
ajrhss-2943	128	6	p	p	NOUN
ajrhss-2943	128	7	,	,	PUNCT
ajrhss-2943	128	8	khaltaev	khaltaev	NOUN
ajrhss-2943	128	9	n	n	CCONJ
ajrhss-2943	128	10	,	,	PUNCT
ajrhss-2943	128	11	aria	aria	PROPN
ajrhss-2943	128	12	workshop	workshop	NOUN
ajrhss-2943	128	13	group	group	NOUN
ajrhss-2943	128	14	,	,	PUNCT
ajrhss-2943	128	15	world	world	NOUN
ajrhss-2943	128	16	health	health	NOUN
ajrhss-2943	128	17	organization	organization	PROPN
ajrhss-2943	128	18	.	.	PUNCT
ajrhss-2943	129	1	allergic	allergic	ADJ
ajrhss-2943	129	2	rhinitis	rhinitis	NOUN
ajrhss-2943	129	3	and	and	CCONJ
ajrhss-2943	129	4	its	its	PRON
ajrhss-2943	129	5	impact	impact	NOUN
ajrhss-2943	129	6	on	on	ADP
ajrhss-2943	129	7	asthma	asthma	NOUN
ajrhss-2943	129	8	.	.	PUNCT
ajrhss-2943	130	1	j	j	PROPN
ajrhss-2943	130	2	allergy	allergy	PROPN
ajrhss-2943	130	3	clin	clin	PROPN
ajrhss-2943	130	4	immunol	immunol	PROPN
ajrhss-2943	130	5	.	.	PUNCT
ajrhss-2943	131	1	2001;108	2001;108	NUM
ajrhss-2943	131	2	:	:	PUNCT
ajrhss-2943	131	3	s147	s147	NUM
ajrhss-2943	131	4	–	–	PUNCT
ajrhss-2943	131	5	s334	s334	PROPN
ajrhss-2943	131	6	.	.	PROPN
ajrhss-2943	132	1	20	20	NUM
ajrhss-2943	132	2	.	.	PUNCT
ajrhss-2943	132	3	blaiss	blaiss	PROPN
ajrhss-2943	132	4	ms	ms	PROPN
ajrhss-2943	132	5	.	.	PROPN
ajrhss-2943	132	6	allergic	allergic	PROPN
ajrhss-2943	132	7	rhinoconjunctivitis	rhinoconjunctivitis	NOUN
ajrhss-2943	132	8	:	:	PUNCT
ajrhss-2943	132	9	burden	burden	NOUN
ajrhss-2943	132	10	of	of	ADP
ajrhss-2943	132	11	disease	disease	NOUN
ajrhss-2943	132	12	.	.	PUNCT
ajrhss-2943	133	1	allergy	allergy	PROPN
ajrhss-2943	133	2	asthma	asthma	PROPN
ajrhss-2943	133	3	proc	proc	PROPN
ajrhss-2943	133	4	.	.	PUNCT
ajrhss-2943	134	1	2007;28:393	2007;28:393	NUM
ajrhss-2943	134	2	–	–	PUNCT
ajrhss-2943	134	3	397	397	NUM
ajrhss-2943	134	4	.	.	PUNCT